Conditions: Retinal Vein Occlusion
Keywords: Visual Acuity Retinal Vein Occlusion Central Retinal Vein Occlusion CRVO
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 6
Healthy volunteers: no

Brief summary:
Background:

\- Central retinal vein occlusion (CRVO) is a blockage of the main vein that carries blood away from the retina in the back of the eye. It can lead to macular edema, a swelling of the retina that is a common source of vision loss. Studies suggest that inflammation might be a cause. Minocycline is a drug that might help prevent cells involved in inflammation from becoming activated. It is approved for use as an antibiotic, but it has not yet been tested to see if it can treat CRVO.

Objectives:

\- To test the safety and effectiveness of minocycline as a treatment for central retinal vein occlusion.

Eligibility:

\- Individuals at least 18 years of age who have central retinal vein occlusion in at least one eye, with vision between 20/32 and 20/200.

Design:

* This study lasts 2 years, with at least 25 visits.
* Participants will be screened with a physical exam and medical history. They will also have blood tests and an eye exam. One eye will be selected as the study eye to receive the medicine.
* Participants will take minocycline or a placebo pill twice a day, about 12 hours apart, for 2 years.
* Participants will have monthly visits for blood tests and full eye exams to study the effect of the treatment. Other exams may include thyroid tests and eye imaging studies. Those in the study may also receive injections of a drug to prevent the growth of new blood vessels in the eye.

Detailed description:
Objective:

Retinal vein occlusions (RVOs) are significant sources of vision loss, affecting mostly healthy people over 55 years of age. The common source of vision loss is the macular edema accompanying the retinal injury. Very recently, studies employing monthly anti-vascular endothelial growth factor (VEGF) treatments have demonstrated a benefit to this line of treatment; however, the duration of effectiveness appears to be short lived and the length of time needed for these monthly injections remains unknown. A histologic study of human retinas with retinal vein occlusions found the presence of activated microglia. Microglia are capable of migrating through the retina to sites of inflammation to associate closely with neurons and the vasculature, and are key cellular players in the mediation of processes of chronic inflammation. For these reasons, microglia represent a promising cellular target for forms of therapy that limit the deleterious inflammatory changes found in vein occlusions. Minocycline, a second-generation tetracycline, has been shown to exhibit anti-inflammatory properties, including microglial inhibition. The objective of this study is to investigate the safety and potential efficacy of minocycline as a microglia inhibitor in participants with central retinal vein occlusion (CRVO).

Study Population:

A minimum of 10 and a maximum of 20 participants who meet the eligibility criteria may be enrolled. Eligibility criteria include: foveal center-involved macular edema secondary to a CRVO, retinal thickness in the central subfield \>350 microns as measured by optical coherence tomography (OCT); and visual acuity (VA) between 20/32 and 20/200 in the study eye.

Design:

In this pilot, double-masked, randomized multi-center study, participants will receive monthly bevacizumab injections for the first three months, followed by PRN dosing. In addition, participants will take an oral dose of 100 mg of minocycline or placebo twice daily for 24 months. During each monthly visit, participants will have their visual acuity measured and will undergo OCT testing to measure retinal thickness. At the Month 3 visit and thereafter, participants will be evaluated for improvement and worsening and will be eligible for additional bevacizumab treatment and/or investigational product (IP) depending on which criteria they fulfill. Additionally, at Month 12, participants will also be evaluated for no improvement.

Outcome Measures:

The primary outcome is the difference in mean change in best-corrected visual acuity (BCVA), as measured in ETDRS letters, between the minocycline and placebo groups in the study eye at 12 months compared to baseline. Secondary outcomes include the difference between the minocycline and placebo groups in the number of intravitreal bevacizumab injections between 12 and 24 months and baseline, changes in mean macular sensitivity as measured by microperimetry at 3, 6, 12, 18 and 24 months compared to baseline, the mean change in BCVA at 24 months compared to baseline, changes in retinal thickness as measured by OCT at 6, 12, 18 and 24 months compared to baseline, number of participants improving greater than or equal to 1 logOCT scale step at 12 and 24 months compared to baseline, as well as and changes in fluid leakage in the macula as demonstrated by fluorescein angiography at 12 and 24 months compared to baseline. Safety outcomes include the number of participant withdrawals, number and severity of systemic and ocular toxicities and the number of adverse events (AEs).

Arms:
arm 1: Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months arm 2: Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months

Interventions: intervention 1: Minocycline intervention 2: Placebo intervention 3: Bevacizumab
Intervention descriptions: intervention 1: 100 mg pink opaque capsule intervention 2: Placebo intervention 3: 1.25 mg bevacizumab injection

Protocol document:
Prot_000.pdf: 
MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page i 
Protocol Title:  A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the 
Treatment of Central Retinal Vein Occlusions 
NCT Number: NCT01468844 
Date of This Submission/Version: September 19, 2018/v19.0 
Principal Investigator 
Catherine Cukras, MD, 
PhD
NEI/NIH 
Building 10, 
Room 10C438
301-435-5061 
cukrasc@nei.nih.gov 
Principal Investigator – Biomedical Research Centre (BRC) Sites 
Clare Bailey, MD 
BEH/ 
UHB 
Bristol Eye 
Hospital 
+44 (0) 7939- 
152-376 
clare.bailey@bristol.ac.uk 
Bishwanath Pal, 
MBBS, MS, Ophth, 
FRCOphth, FRCSEdin 
MEH 
Moorfields 
Eye Hospital 
+44 (0) 207-
566-2419 
Bishwanath.Pal@moorfiel
ds.nhs.uk 
Lead Associate Investigator 
Wai Wong, MD, PhD 
NEI/NIH 
Building 6, 
Room 217 
301-496-7566 
wongw@nei.nih.gov 
Associate Investigators 
Emily Y. Chew, MD 
NEI/NIH 
Building 10, 
Room 3-2531 
301-496-6583 
echew@nei.nih.gov 
Henry Wiley, MD 
NEI/NIH 
Building 10, 
Room 10D45
301-451-4261 
wileyhe@nei.nih.gov 
Awilda V. Holland, 
DNP, MSHSc, RN, 
CCRP
NIH/NEI 
Building 10, 
Room 10D45 
301-435-1831 
aholland@mail.nih.gov 
Angela Kibiy, MPH, 
BSN, RN 
NEI/NIH 
Building 10, 
Room 10D45
301-435-1833 
angela.kibiy@nih.gov 
Alexander Kaplan, MD 
NIH/NEI 
Building 10, 
Room 10D45 
301-443-8557 
alex.kaplan@nih.gov 
Munir Iqbal, MD, 
FRCSC 
NIH/NEI 
Building 10, 
Room 3-2531 
301-496-6583 
munir.iqbal@nih.gov 
Christopher Hwang, 
MD 
NIH/NEI 
Building 10, 
Room 3-2531 
301-496-6583 
christopher.hwang@nih.gov 
Medically Accountable Investigator 
Emily Y. Chew, MD 
NEI/NIH 
Building 10, 
Room 3-2531 
301-496-6583 
echew@nei.nih.gov 
Research Contact  
Angela Kibiy, MPH, 
BSN, RN 
NEI/NIH 
Building 10, 
Room 10D45
301-435-1833 
angela.kibiy@nih.gov 
 
 
 


MiCRVO 
September 19, 2018 
 
Version 19.0 
CONFIDENTIAL 
Page ii 
Coordinating Center : 
The Emmes Corporation (Emmes) 
401 North Washington St., Suite 700 
Rockville, MD 20850 USA 
Phone: (301) 251-1161 
Facsimile: (202) 478-0243 
 
Participating Site: 
 
Bristol Eye Hospital (BEH) 
Lower Maudlin Street 
Bristol BS1 2LX, UK 
Phone: +4401173424613 
Facsimile: +4401173424721 
 
Moorfields Eye Hospital (MEH) 
The John Saunders Suite 
9-11 Bath Street 
London EC1V 9LF, UK 
Phone: +44 (0) 2075-662-419 
Fax: +44 (0) 2075-662-972 
 
Human Research Protections Program Investigator and Staff Training: 
“Just in time” human subjects protection training courses are required for investigators and staff 
participating on this protocol: None 
 
Total Requested Accrual: 
20 
Participants – A minimum of 10 and a maximum of  
20 participants will be accrued. 
0 
Healthy Volunteers 
 
Project Uses Ionizing Radiation:  
 No 
 Yes 
 
IND/IDE: 
 No  
 Yes 
Drug/Device #: 
108,154 
Sponsor:  
Catherine Cukras, MD, PhD 
 
EudraCT: 
 
 
 
 
 No   
 Yes 
 
Drug/Device #: 
2017-001143-12 
 
Chief Investigator:  
Clare Bailey, MD 
 
Durable Power of Attorney: 
 No  
 Yes 
 
Multi-institutional Project: 
 No  
 Yes 
 
 


MiCRVO 
September 19, 2018 
 
Version 19.0 
CONFIDENTIAL 
Page iii 
Site 
FWA 
Coordinating Center: National Eye Institute (NEI) 
FWA00005897 
Participating Center: Bristol Eye Hospital (BEH) 
Principal Investigator: Clare Bailey, MD
FWA00000523 
Participating Center: Moorfields Eye Hospital (MEH) 
Principal Investigator: Bishwanath Pal, MBBS, MS, Ophth, FRCOphth, 
FRCSEdin 
FWA00010199 
 
Additional sites may be identified and added to this study in future amendments. 
Data and Safety Monitoring Board: 
 No  
 Yes 
 
Technology Transfer Agreement:   
 No   
 Yes 
 
Samples Being Stored for Future Use:  
 No  
 Yes 
 
Flesch-Kincaid Reading Level of Consent Form:  
9.5 


MiCRVO 
September 19, 2018 
 
Version 19.0 
CONFIDENTIAL 
Page iv 
TABLE OF CONTENTS 
PROTOCOL ABBREVIATIONS LIST ................................................................................................ VI 
PRÉCIS ............................................................................................................................................ 1 
1.0 INTRODUCTION/SCIENTIFIC RATIONALE ............................................................................. 3 
1.1 
Central Retinal Vein Occlusions ..................................................................................... 3 
1.2 
Current Treatments of CRVO ......................................................................................... 4 
1.3 
Role of Microglia ............................................................................................................ 4 
1.4 
Role of Microglia in Retinal Vein Occlusions ................................................................ 5 
1.5 
Minocycline as a Microglia Inhibitor ............................................................................. 6 
1.5.1 
Minocycline ................................................................................................................ 6 
1.5.2 
Preclinical Studies with Minocycline ......................................................................... 7 
1.5.3 
Clinical Use and Clinical Studies with Minocycline .................................................. 7 
2.0 STUDY OBJECTIVE ................................................................................................................. 8 
3.0 PARTICIPANTS ....................................................................................................................... 8 
3.1 
Participant Eligibility Criteria ......................................................................................... 8 
3.1.1 
Inclusion Criteria ........................................................................................................ 8 
3.1.2 
Exclusion Criteria ..................................................................................................... 10 
3.2 
Study Eye Eligibility Criteria........................................................................................ 11 
3.2.1 
Study Eye Inclusion Criteria ..................................................................................... 11 
3.2.2 
Study Eye Exclusion Criteria .................................................................................... 12 
3.2.3 
Study Eye Selection Criteria in Cases of Bilateral Disease ...................................... 13 
4.0 STUDY DESIGN AND METHODS ........................................................................................... 13 
4.1 
Study Overview ............................................................................................................ 13 
4.2 
Recruitment ................................................................................................................... 13 
4.3 
Screening....................................................................................................................... 14 
4.4 
Randomization, Masking and Unmasking .................................................................... 15 
4.5 
Study Design and Procedures ....................................................................................... 15 
4.5.1 
Treatment Prior to Month 3 ...................................................................................... 18 
4.5.2 
Treatment Beginning at Month 3 .............................................................................. 18 
4.6 
Ocular and Systemic Evaluations ................................................................................. 21 
4.6.1 
Reporting of Expected Events .................................................................................. 22 
4.7 
Study and Concomitant Therapy .................................................................................. 23 
4.7.1 
Minocycline Formulation at Pine Pharmaceuticals .................................................. 23 
4.7.2 
Minocycline Formulation for BRC Sites .................................................................. 23 
4.7.3 
Placebo Formulation at Pine Pharmaceuticals .......................................................... 23 
4.7.4 
Placebo Formulation for BRC Sites .......................................................................... 24 
4.7.5 
Dosage, Administration and Storage ........................................................................ 24 
4.7.6 
Concomitant Therapy................................................................................................ 24 
4.8 
Investigational Product Accountability ......................................................................... 24 
4.9 
Follow-up/Termination Procedures .............................................................................. 25 
4.10 
Storage of Samples and Data ........................................................................................ 25 
 
 
 


MiCRVO 
May 31, 2018 
 
TABLE OF CONTENTS (CONTINUED) 
Version 19.0 
CONFIDENTIAL 
Page v 
5.0 RISKS/DISCOMFORTS .......................................................................................................... 25 
5.1 
Intravitreal Bevacizumab Risks .................................................................................... 27 
5.2 
Investigational Product Risks ....................................................................................... 27 
5.2.1 
Minocycline-related .................................................................................................. 27 
5.2.2 
Drug Interaction-related ............................................................................................ 29 
5.2.3 
Placebo-related .......................................................................................................... 29 
6.0 PARTICIPANT MONITORING ................................................................................................ 29 
6.1 
Individual Withdrawal Criteria ..................................................................................... 29 
6.2 
Pregnancy Monitoring .................................................................................................. 30 
7.0 OUTCOME MEASURES ......................................................................................................... 31 
7.1 
Primary Outcome .......................................................................................................... 31 
7.2 
Secondary Outcomes .................................................................................................... 31 
7.3 
Safety Outcomes ........................................................................................................... 32 
8.0 STATISTICAL ANALYSIS ...................................................................................................... 32 
9.0 HUMAN PARTICIPANTS PROTECTION ................................................................................. 34 
9.1 
Equitability .................................................................................................................... 34 
9.1.1 
Justification for Exclusion of Children ..................................................................... 34 
9.1.2 
Justification for Exclusion of Pregnant or Lactating Women ................................... 35 
9.2 
Qualifications of Investigators ...................................................................................... 35 
9.2.1 
Professional Licensure .............................................................................................. 37 
10.0 ANTICIPATED BENEFITS ...................................................................................................... 38 
11.0 CLASSIFICATION OF RISK ................................................................................................... 38 
12.0 CONSENT DOCUMENTS AND PROCESS ................................................................................ 38 
12.1 
Unanticipated Enrollment of Non-English Speaking Participants at the NEI .............. 39 
13.0 DATA AND SAFETY MONITORING ....................................................................................... 39 
13.1 
Coordinating Center ...................................................................................................... 40 
13.2 
Data and Safety Monitoring Committee ....................................................................... 40 
13.3 
Criteria for Stopping the Study ..................................................................................... 41 
14.0 QUALITY ASSURANCE ......................................................................................................... 41 
15.0 REPORTING OF UNANTICIPATED PROBLEMS, ADVERSE EVENTS AND PROTOCOL 
DEVIATIONS .................................................................................................................................. 42 
16.0 ALTERNATIVE THERAPIES .................................................................................................. 43 
17.0 PRIVACY .............................................................................................................................. 43 
18.0 CONFIDENTIALITY ............................................................................................................... 43 
19.0 CONFLICT OF INTEREST ...................................................................................................... 44 
20.0 TECHNOLOGY TRANSFER.................................................................................................... 44 
21.0 RESEARCH AND TRAVEL COMPENSATION.......................................................................... 44 
22.0 REFERENCES ........................................................................................................................ 45 
APPENDIX 1: DETERMINING CHILDBEARING POTENTIAL .......................................................... 49 
APPENDIX 2: STUDY FLOWSHEET ................................................................................................ 50 
APPENDIX 3: LIST OF DEFINITIONS ............................................................................................. 52 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page vi 
PROTOCOL ABBREVIATIONS LIST 
AE
Adverse Event 
ALS 
Amyotrophic Lateral Sclerosis 
APD 
Afferent Pupillary Defect
BCVA
Best Corrected Visual Acuity 
BEH 
Bristol Eye Hospital 
BRB 
Blood-Retinal Barrier
BRC 
Biomedical Research Centre 
BRVO
Branch Retinal Vein Occlusion 
BUN
Blood Urea Nitrogen 
CBC 
Complete Blood Count 
CC
Clinical Center 
CD
Clinical Director 
CD-68 
Clusters of Differentiation 68 
CFP
Color Fundus Photography
CFR 
Code of Federal Regulation 
CNS 
Central Nervous System
CNS IRB
Combined NeuroScience Institutional Review Board
COX-2 
Cyclooxygenase-2 
CRIS 
Clinical Research Information System
CTCAE
Common Terminology Criteria for Adverse Events
CVA
Cerebral Vascular Event
DME 
Diabetic Macular Edema 
DSMC
Data and Safety Monitoring Committee 
Emmes 
The Emmes Corporation
EMR
Electronic Medical Record 
ETDRS
Early Treatment Diabetic Retinopathy Study
EudraCT 
European Clinical Trials Database 
FA 
Fluorescein Angiogram
FDA 
Food and Drug Administration
FGF
Fibroblast Growth Factor
FSH
Follicle-Stimulating Hormone
HRPP
Human Research Protections Program
HRVO
Hemi-Retinal Vein Occlusion
ICE 
IL-1b-Converting Enzyme 
ICRRC 
Intramural Clinical Research Review Committee 
IL-1b 
Interleukin-1b
IL-6
Interleukin-6 
IL-8
Interleukin-8 
IND
Investigational New Drug 
IOP 
Intraocular Pressure


MiCRVO 
September 19, 2018 
 
PROTOCOL ABBREVIATIONS LIST (CONTINUED) 
 
Version 19.0 
CONFIDENTIAL 
Page vii 
IP 
Investigational Product 
IRB
Institutional Review Board
MCP-1 
Monocyte Chemoattractant Protein 
MEH 
Moorfields Eye Hospital
MHRA 
Medicines & Healthcare products Regulatory Agency
MI 
Myocardial Infarction
MMP 
Matrix Metalloproteinase
MS
Multiple Sclerosis
NEI
National Eye Institute
NGF 
Nerve Growth Factor 
NIH
National Institutes of Health 
NO
Nitric Oxide
OB/GYN 
Obstetrics and Gynaecology
OCT 
Optical Coherence Tomography 
OHSRP
Office of Human Subject Research Protection 
ONL
Outer Nuclear Layer 
PI 
Principal Investigator
PTMS 
Protocol Tracking and Management System 
QA
Quality Assurance 
RVO
Retinal Vein Occlusion
SAE 
Serious Adverse Event 
SOP
Standard Operating Procedure 
SPF
Sun Protection Factor
STZ
Streptozotocin
SUSAR
Serious Unanticipated Serious Adverse Reaction 
TNFa 
Tumor Necrosis Factor-a 
USP
United States Pharmacopeia
UV
Ultraviolet
VA
Visual Acuity 
VEGF 
Vascular Endothelial Growth Factor
YAG
Yttrium Aluminum Garnet 


MiCRVO 
 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 1 
PRÉCIS 
Objective: Retinal vein occlusions (RVOs) are significant sources of vision loss, affecting mostly 
healthy people over 55 years of age. The common source of vision loss is the macular edema 
accompanying the retinal injury. Very recently, studies employing monthly anti-vascular 
endothelial growth factor (VEGF) treatments have demonstrated a benefit to this line of treatment; 
however, the duration of effectiveness appears to be short lived and the length of time needed for 
these monthly injections remains unknown. A histologic study of human retinas with RVOs found 
the presence of activated microglia. Microglia are capable of migrating through the retina to sites 
of inflammation to associate closely with neurons and the vasculature, and are key cellular players 
in the mediation of processes of chronic inflammation. For these reasons, microglia represent a 
promising cellular target for forms of therapy that limit the deleterious inflammatory changes 
found in vein occlusions. Minocycline, a second-generation tetracycline, has been shown to exhibit 
anti-inflammatory properties, including microglial inhibition. The objective of this study is to 
investigate the safety and potential efficacy of minocycline as a microglia inhibitor in participants 
with central retinal vein occlusion (CRVO). 
Study Population: A minimum of 10 and a maximum of 20 participants who meet the eligibility 
criteria may be enrolled. Eligibility criteria include: foveal center-involved macular edema 
secondary to a CRVO, retinal thickness in the central subfield > 350 microns as measured by 
optical coherence tomography (OCT); and visual acuity (VA) between 20/32 and 20/200 in the 
study eye. 
Design: In this pilot, double-masked, randomized multi-center study, participants will receive 
monthly bevacizumab injections for the first three months, followed by PRN dosing. In addition, 
participants will take an oral dose of 100 mg of minocycline or placebo twice daily for 24 months. 
During each monthly visit, participants will have their visual acuity measured and will undergo 
OCT testing to measure retinal thickness. At the Month 3 visit and thereafter, participants will be 
evaluated for “improvement” and “worsening” and will be eligible for additional bevacizumab 
treatment and/or investigational product (IP) depending on which criteria they fulfill.  
Additionally, at Month 12, participants will also be evaluated for “no improvement.” 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 2 
Outcome Measures: The primary outcome is the difference in mean change in best-corrected 
visual acuity (BCVA), as measured in ETDRS letters, between the minocycline and placebo 
groups in the study eye at 12 months compared to baseline. Secondary outcomes include the 
difference between the minocycline and placebo groups in the number of intravitreal bevacizumab 
injections between 12 and 24 months and baseline, changes in mean macular sensitivity as 
measured by microperimetry at 3, 6, 12, 18 and 24 months compared to baseline, the mean change 
in BCVA at 24 months compared to baseline, changes in retinal thickness as measured by OCT at 
6, 12, 18 and 24 months compared to baseline, number of participants improving ≥ 1 logOCT scale 
step at 12 and 24 months compared to baseline, as well as and changes in fluid leakage in the 
macula as demonstrated by fluorescein angiography at 12 and 24 months compared to baseline. 
Safety outcomes include the number of participant withdrawals, number and severity of systemic 
and ocular toxicities and the number of adverse events (AEs). 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 3 
1.0 
INTRODUCTION/SCIENTIFIC RATIONALE 
1.1 
Central Retinal Vein Occlusions 
Retinal vein occlusions are a significant source of vision loss, affecting mostly healthy people over 
55 years of age. The common source of vision loss is the macular edema accompanying the retinal 
injury. The two main types of retinal vein occlusions are central retinal vein occlusions (CRVO) 
and branch retinal vein occlusions (BRVO). The prevalence of CRVO is approximately 0.1%.1,2 
The standard-of-care for CRVO is even more limited than for BRVO. While optic nerve 
sheathotomy and other invasive measures have been tried, these interventions have not been 
successfully proven in a large randomized clinical trial. Very recently the Central Retinal Vein 
OcclUsIon Study: Evaluation of Efficacy and Safety (CRUISE), a phase III multicenter trial, 
reported six-month outcome results demonstrating efficacy of intravitreal ranibizumab injections 
for the treatment of CRVO.3 The CRUISE study, while encouraging, only has six-month results 
published and requires monthly intravitreal injections with no clear treatment endpoint. 
Ranibizumab has very recently gained FDA approval for the indication of vein occlusions and the 
labeling includes recommendations for monthly intravitreal injections. 
The fundamental cause of macular edema associated with retinal vein occlusions is not understood 
completely, but it is increasingly clear that its pathophysiology extends beyond microvascular 
disease to involve immune mediators in the retina. While hydrostatic stress following the  
break-down of the blood-retinal barrier (BRB) can partly contribute to retinal edema, tissue 
responses to hypoxia are also likely to play a role. In the aftermath of a retinal vein occlusion, 
tissue hypoxia induces the expression of several cytokines, including monocyte chemoattractant 
protein (MCP-1), leading to the activation of inflammatory cells, such as macrophages and 
microglia, which are then attracted to the hypoxic retinal areas.4 Activated microglia release  
TNF-α which triggers the production of interleukin-8 (IL-8), VEGF, basic fibroglast growth factor 
(FGF) and MCP-1 in retinal vascular cells and glial cells adjacent to the microvessels.5 A study on 
patients with BRVO examined the concentrations of VEGF and interleukin-6 (IL-6) in the aqueous 
humor and found that these cytokine levels were increased in the setting of retinal vein occlusion.6  
Further, a histologic study of human retinas with retinal vein occlusions found numerous cluster 
of differentiation-68 (CD-68) positive cells surrounding the vasculature indicating the presence of 
activated microglia.7 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 4 
Inflammation may represent an early adaptive response to metabolic derangements in the ischemic 
retina; over time; however, it leads to progressive vascular damage results, culminating in macular 
edema and neovascularization.8 As such, there may be a feasible therapeutic rationale to broadly 
limit and down-regulate the level of microglia-mediated chronic inflammation in the treatment of 
RVOs. 
1.2 
Current Treatments of CRVO 
Unlike branch retinal vein occlusions, CRVOs did not demonstrate an improvement in visual 
acuity with focal laser photocoagulation.9 Several more invasive therapies have been pursued 
including optic neurotomy and sheathotomy. However, none have shown efficacy in a randomized 
controlled clinical trial. In fact, a review of CRVO intervention treatments in 2007 concluded that 
there was limited evidence for any intervention to improve visual acuity in patients with CRVO.10 
Recently, phase III results of the CRUISE study, have demonstrated efficacy of monthly injections 
of ranibizumab for treatment of central retinal vein occlusions.3 And in late June 2010, the FDA 
approved ranibizumab for use in the treatment of retinal vein occlusions. 
However, while the treatment of monthly injections appears beneficial in the short term, the longer 
term result of this course of treatment is unknown. Also unknown, is the number of injections 
required, and the durability of these injections. While being a major breakthrough in the field of 
treatment of these retinal conditions, monthly anti-VEGF injections still have limitations for 
treating this disease. 
We propose to study minocycline as a microglia inhibitor which can modulate the activation of 
microglia, alter the cytokine profile present, and thus may be useful in the treatment of CRVO. 
1.3 
Role of Microglia 
Retinal microglia, derived from the monocytic lineage, are resident cells in the healthy retina, and 
may be construed as representatives of the immune system in the immune-privileged environment 
of the retina. Microglia are related to macrophages but are a distinct entity11 comprising 
approximately 5% to 20% of the total glial cell population in the central nervous system (CNS).12 
Microglia in the CNS are important sources of inflammatory cytokines and chemokines, and are 
the primary cellular mediators of immune function.13 Most of the factors released by activated 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 5 
microglia are proinflammatory and neurotoxic, including cytokines tumor necrosis factor-a 
(TNFa) and interleukin-1b (IL-1b), free radicals such as NO and superoxide, fatty acid metabolites 
such as eicosanoids, and quinolinic acid.14 The activation of microglia has been implicated in the 
pathogenesis of many neurodegenerative diseases including Alzheimer’s, Parkinson’s disease, 
HIV-related dementia, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS) and prion 
diseases.15 The cytokines released by activated microglia are thought to speed neurodegeneration. 
Microglia have also been implicated in ischemic and mechanical injury to the brain.16 In the retina, 
retinal glial cells consist of macroglia (Müller cells and astrocytes) and microglia. Microglia are 
able to migrate in various retinal disease states. In photic injury, microglia migrate from the inner 
retinal layers to the outer nuclear layer (ONL) and also into the subretinal space.17,18 In sites of 
inflammation, these cells migrate through the retina to closely associate with neurons and the 
vasculature, and are key cellular players in the mediation of processes of chronic inflammation. 
As such, it is likely that retina microglia play an important role in the inflammatory etiology of 
diabetic retinopathy. 
1.4 
Role of Microglia in Retinal Vein Occlusions 
There is accumulating evidence that retinal microglia are indeed associated with inflammation in 
the retina in conditions such as diabetic retinopathy and RVOs. While diabetic retinopathy is often 
thought of as a vasculopathy, there is a growing body of evidence to suggest that changes in the 
retinal neurons precede vascular changes.19 Microglia function has been investigated in a diabetic 
animal model where diabetes was induced in rats with the injection of streptozotocin (STZ). 
Animal models of diabetes have indicated a role of microglia activation in diabetic retinopathy.  
In a histologic study of microglia in eyes with diabetic retinopathy, Zeng et al. reported that 
microglia increase in number and exhibit hypertrophic features as well as an up-regulation of 
markers in diseased states and marked microglia surrounding the retinal vasculature, labeled 
“microglia perivasculitis” in further stages of disease.20 This may lead to early fluorescein leakage 
present before frank vasculopathy is noticed clinically both in diabetic retinopathy and vein 
occlusion injury. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 6 
Animal models of ischemia/reperfusion injury mimics the mechanism of injury occurring in 
RVOs. Shin et al. used both an ischemia/reperfusion model as well as a venous cauterization 
method to demonstrate that microglia become activated under these circumstances and migrate to 
the inner plexiform layer near blood vessels.21 Further research by Lin et al. on an ischemia/ 
reperfusion model in rats have shown that not only are microglia activated in this model, but also 
that they can be inhibited by minocycline.22 In their model, they demonstrated a significant 
treatment effect of treatment in rats with minocycline inhibiting the vascular permeability response 
by inhibiting microglia. 
Indeed, focal laser photocoagulation, the long-time standard-of-care treatment for Diabetic 
Macular Edema (DME) and for branch retinal vein occlusion (BRVO), recently has been found to 
induce prompt changes in the morphology and behavior of retinal microglia, and may thus also 
involve microglia in their therapeutic effect.23 For these reasons, microglia represent a promising 
cellular target for forms of therapy that limit the deleterious inflammatory changes found in vein 
occlusions. While therapeutic agents that specifically inhibit individual pro-inflammatory 
molecules one at a time may have efficacy, an approach that targets the cellular mediator, the 
microglia cell, may have broader and more relevant effects. 
1.5 
Minocycline as a Microglia Inhibitor 
1.5.1 Minocycline 
Minocycline is a second-generation tetracycline, which has anti-inflammatory properties that are 
separate from its anti-microbial properties. Minocycline has high lipophilicity, which leads to both 
excellent bioavailability and ability to cross the blood-brain barrier24 and appears to inhibit the 
activation of microglia, but not astrocytes.25 The mechanism of neuroprotection by minocycline is 
likely several-fold and includes: anti-inflammatory effects, reduction of matrix metalloproteinase 
(MMP) activity,26 and decrease in NO production, ultimately leading to an inhibition of microglia 
and of cell death.27 Minocycline can exert its anti-inflammatory effects on microglia in culture, 
inhibiting their proliferation and release of IL-1B, IL-6, TNF-, NO secretion, and  
NGF-production leading to neuroprotection with the inhibition of cell death.28-32 Minocycline has 
been also found to inhibit induction of IL-1b-converting enzyme (ICE) mRNA25 which means that 
minocycline may function by reducing cytotoxic properties of microglia which can be activated 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 7 
by ischemia and neuroexcitation. In addition, minocycline can also help prevent cytokine-induced 
activation of microglia and prevent further production of proinflammatory stimuli. 
1.5.2 Preclinical Studies with Minocycline 
In animal models of global and focal cerebral ischemia, traumatic brain and spinal injury, 
minocycline treatment showed a reduction in lesion size in conjunction with the inhibition of 
microglial cells.33-36 In rodent models of spinal cord injury, treatment with minocycline not only 
reduced lesion size and improved histological parameters but also improved neurological function 
such as hind limb function and strength.37 
Minocycline has also been studied in the context of ocular diseases. In mouse models of glaucoma, 
minocycline successfully decreased microglial activation and retinal ganglion cell axonal transport 
and improved optic nerve integrity.38 Minocycline was effective in decreasing retinal microglia 
activation in culture.39 In models of inherited and light-induced retinal degeneration, minocycline 
was effective in delaying photoreceptor cell death.39,40 As mentioned above, minocycline reduces 
apoptotic cell death in mouse models of diabetic retinopathy.32 Animal studies have also indicated 
that inhibiting microglia activation with minocycline was useful in decreasing the level of pro-
inflammatory mediators and preventing diabetes-induced cell death in the retina.32 In particular, 
addition of minocycline to TNF-alpha-activated microglia was found to prevent the release of 
COX-2, an enzyme important in prostaglandin synthesis and is a robust marker of inflammation.32  
Ultimately, diabetic rats do demonstrate an increased rate of apoptosis, as evidenced by increased 
caspase-3 activity, and minocycline has been shown to decrease that activation.32 
1.5.3 Clinical Use and Clinical Studies with Minocycline 
Minocycline is a member of the tetracycline family of antibiotics that has good CNS bioavailability 
following oral administration. It is FDA-approved for treating many infections including skin 
infections caused by Staphylococcus aureus and is often used in ophthalmology to treat blepharitis 
and ocular rosacea. It has a favorable side-effect profile, although it should not be used in 
pregnancy as the use of tetracycline class of drugs during tooth development may cause permanent 
discoloration of the teeth. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 8 
Minocycline is used widely and has been shown to be well tolerated when used at the  
FDA-approved doses proposed in this study. Based on studies examining the adverse events (AEs) 
reported between 1998 and 2003, and the number of prescriptions for minocycline, the rate of AEs 
has been reported as 72 AEs per million prescriptions averaging to 13 per million per year.41  
The majority of these events were gastrointestinal upset, photosensitivity, hyperpigmentation and 
tooth discoloration.41 
Its application in clinical trials as an anti-microglia agent include a large clinical trial of  
152 patients with acute stroke in which patients treated with 200 mg minocycline for five days had 
a significantly better neurological outcome compared with placebo.27 Other ongoing clinical 
studies include the use of minocycline to decrease symptom progression in Huntington’s disease 
(NCT00277355), and to provide neuroprotective effects in Parkinson’s disease (NCT00063193) 
and in ALS (NCT00047723). 
A current clinical trial, conducted by the Penn State Diabetic Retinopathy Center, is commencing 
recruitment to examine the effects of a related tetracycline, doxycycline, in its ability to slow the 
deterioration or improve retinal function and/or induce regression, or slow progression, of diabetic 
retinopathy (NCT00511875). 
2.0 
STUDY OBJECTIVE 
The study objective is to investigate the safety and potential efficacy of minocycline, a microglia 
inhibitor, in the treatment of CRVO. 
3.0 
PARTICIPANTS 
The accrual ceiling is 20 participants who meet the eligibility criteria. 
3.1 
Participant Eligibility Criteria 
3.1.1 Inclusion Criteria 
To be eligible, the following participant-level inclusion criteria must be met, where applicable. 
1. Participant is 18 years of age or older. 
2. Participant must understand and sign the protocol’s informed consent document. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 9 
3. Female participants of childbearing potential (see Appendix 1 for definition) must not be 
pregnant or breast-feeding and must be willing to undergo serum (BRC sites only) and 
urine pregnancy tests throughout the study. 
4a. For the NEI Site: Female participants of childbearing potential (see Appendix 1 for 
definition) and male participants able to father children must have (or have a partner who 
has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must 
agree to practice two acceptable methods of contraception throughout the course of the 
study and for one week after study medication discontinuation (based on the half life of 
minocycline which is 11-22 hours). Acceptable methods of contraception include: 
 hormonal contraception (i.e., birth control pills*, injected hormones, dermal patch or 
vaginal ring), 
 intrauterine device, 
 barrier methods (diaphragm, condom) with spermicide, or 
 surgical sterilization (hysterectomy or tubal ligation). 
*Oral birth control pills must be used with caution as minocycline decreases the 
effectiveness of some oral contraceptives. Participants already taking oral contraceptives 
may continue to use them, but must agree to use at least one other method of birth control 
while on study. 
4b. For the BRC Sites: Female participants of childbearing potential (see Appendix 1 for 
definition) and male participants able to father children must have (or have a partner who 
has) had a hysterectomy or vasectomy, or be completely abstinent from intercourse.  
Male participants or male partners (of female participants) who have not had a vasectomy 
or are not abstinent are required to use a condom with spermicide throughout the course of 
the study and for one week after study medication discontinuation (based on the half life 
of minocycline which is 11-22 hours). Female participants of childbearing potential or 
female partners (of male participants) of childbearing potential must practice one of the 
below acceptable methods of contraception throughout the course of the study and for one 
week after study medication discontinuation: 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 10 
 hormonal contraception (i.e., birth control pills*, injected hormones, dermal patch or 
vaginal ring), 
 intrauterine device, 
 barrier methods (e.g., diaphragm) with spermicide, or 
 surgical sterilization (hysterectomy or tubal ligation). 
Abstinence is only acceptable when it is the participant’s preferred and usual lifestyle 
choice. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. 
*Oral birth control pills must be used with caution as minocycline decreases the 
effectiveness of some oral contraceptives. Participants already taking oral contraceptives 
may continue to use them, but must agree to use at least one other method of birth control 
while on study. 
It should be noted that two forms of contraception (as specified above) will be used by 
sexually active participants for the duration of the study and for one week after study 
medication discontinuation. 
5. Participants must agree to notify the study investigator or coordinator if any of their doctors 
initiate a new medication during the course of this study. 
6. Participant must have normal renal function and liver function, or have mild abnormalities 
not above grade 1 as defined by the Common Terminology Criteria for AEs v4.0 (CTCAE). 
7. Participant must agree to minimize exposure to sunlight or artificial UV rays and to wear 
protective clothing, sunglasses, and sunscreen (minimum SPF 15) if s/he must be out in the 
sun. 
8. Participant has at least one eye that meets the study eye criteria listed in Section 3.2 below. 
3.1.2 Exclusion Criteria 
A participant is not eligible if any of the following exclusion criteria are present. 
1. Participant is in another investigational study and actively receiving IP for CRVOs. 
2. Participant is unable to comply with study procedures or follow-up visits. 
3. Participant has a known hypersensitivity to sodium fluorescein dye. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 11 
4. Participant has a condition that, in the opinion of the investigator, would preclude 
participation in the study (e.g., unstable medical status including blood pressure and 
glycemic control). 
5. Participant has a history of chronic renal failure requiring dialysis or kidney transplant. 
6. Participant has a history of chronic hepatitis or liver failure. 
7. Participant has an allergy or hypersensitivity to minocycline or any drug in the tetracycline 
family. 
8. Participant is currently taking a tetracycline medication. 
9. Participant is taking any medication that could adversely interact with minocycline such as 
methoxyflurane. 
10. Participant has a blood pressure of > 180/110 (systolic above 180 OR diastolic above 110). 
 If blood pressure is brought below 180/110 by anti-hypertensive treatment, the 
participant can become eligible. 
11. Participant is currently being treated with systemic anti-VEGF agents or systemic steroids. 
12. Participant had a cerebral vascular event (CVA) or myocardial infarction (MI) within three 
months prior study entry. 
13. Participant has a history of thyroid cancer. 
3.2 
Study Eye Eligibility Criteria 
The participant must have at least one eye meeting all inclusion criteria and none of the exclusion 
criteria listed below. 
3.2.1 Study Eye Inclusion Criteria 
1. The study eye has a best-corrected ETDRS visual acuity score between 78 and 34 letters 
(i.e., between 20/32 and 20/200). 
2. The study eye shows definite retinal thickening due to a CRVO based on clinical 
examination involving the center of the macula that is not refractory to further therapy as 
based on the investigator’s clinical judgment. CRVO is defined as an eye that had retinal 
hemorrhage or other biomicroscopic evidence of RVO (e.g., telangiectatic capillary bed) 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 12 
and a dilated (or previously dilated) venous system in at least three quadrants of the retina 
drained by the affected vein. 
3. The study eye has retinal thickness in the central subfield on baseline OCT measurement 
> 350 microns, as measured by Zeiss Cirrus spectral domain OCT, or an equivalent retinal 
thickness on a similar OCT machine. 
4. The study eye has media clarity and pupillary dilation sufficient for adequate fundus 
photographs. Furthermore, the participant must be able to cooperate during the procedure 
for accurate fundus photographs. 
3.2.2 Study Eye Exclusion Criteria 
1. Macular edema is considered to be due to a cause other than CRVO. 
2. An eye should not be considered eligible if: 
 The macular edema is considered to be related to cataract extraction, or 
 Clinical examination and/or OCT suggest that vitreoretinal interface disease (e.g., a 
taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular 
edema, or 
 Clinical examination, medical history and/or fluorescein angiography suggest that 
diabetic retinopathy is the primary cause of the edema. 
3. The study eye has a history of a recurrent RVO. 
4. The study eye has a history of RVO present for >18 months. 
5. A brisk afferent pupillary defect (APD) is present in the study eye. 
6. An ocular condition (other than RVO) is present such that, in the opinion of the 
investigator, visual acuity would not improve from resolution of macular edema  
(e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, laser scar at 
fovea, non-retinal condition). 
7. An ocular condition (other than RVO) is present that, in the opinion of the investigator, 
might affect macular edema or alter visual acuity during the course of the study  
(e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, 
Irvine-Gass Syndrome, etc.). 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 13 
8. A substantial cataract that, in the opinion of the investigator, is likely to be decreasing 
visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or 
worse if eye was otherwise normal) is present in the study eye. 
9. The study eye has had panretinal or sectoral scatter photocoagulation (PRP) within four 
months prior to study entry. 
10. The study eye has had pars plana vitrectomy within six months prior to study entry. 
11. The study eye has undergone major ocular surgery (including cataract extraction, scleral 
buckle, any intraocular surgery, etc.) within three months prior to study entry. 
12. A yttrium aluminum garnet (YAG) capsulotomy has been performed on the study eye 
within two months prior to study entry. 
13. The study eye has had treatment < 3 months prior to study entry of intravitreal or periocular 
steroid injections. 
14. The study eye has had treatment < 28 days prior to study entry of intravitreal anti-VEGF 
agents. 
3.2.3 Study Eye Selection Criteria in Cases of Bilateral Disease 
If both eyes of a participant meet the criteria described in Sections 3.2.1 and 3.2.2, the study eye 
will be determined at the investigator’s discretion. 
4.0 
STUDY DESIGN AND METHODS 
4.1 
Study Overview 
This is a pilot, double-masked, randomized, multi-center study to investigate the safety and 
potential efficacy of minocycline as a microglia inhibitor in participants with CRVO who are 
concurrently being treated with standard-of-care anti-VEGF (bevacizumab) intravitreal injections. 
This study is designed not to determine efficacy but rather to generate preliminary data to support 
a fully powered phase III study. 
4.2 
Recruitment 
Up to 20 participants will be recruited from the NEI clinic and BRC sites, collectively.  
The recruitment totals are not fixed at either the NEI or BRC sites. 
NIH recruitment will occur by self-referral and referral from outside physicians will be permitted. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 14 
A letter will be provided to local ophthalmologists to assist with recruitment. A recruitment flyer 
will be posted at community gathering places including but not limited to: hospitals, libraries, 
senior centers, senior housing facilities, area metro and bus stops, websites, newspapers and 
throughout the NIH campus. NIH investigators from this study working at the Veterans Affairs 
hospital will provide information to patients in the Veterans Affairs eye clinic, but will not perform 
a formal assessment of eligibility or conduct any part of the informed consent process at the 
Veterans Affairs hospital. Potentially interested patients will contact the investigators at a later 
time. Contact information from Veterans Affairs patients will be provided to the NIH investigators 
only if the patient specifically requests that someone call them to set up the initial visit.  
The interaction will be documented in the medical record at the Veterans Affairs clinic. 
Participants at the BRC sites will be identified following attendance at routine appointments or 
sent a recruitment letter from existing databases of patients diagnosed with CRVO and who 
routinely attend the BRC sites for treatment. 
4.3 
Screening 
Potential participants at the NEI will be screened under the NEI screening (08-EI-0102) or 
evaluation and treatment protocol (08-EI-0169) to establish eligibility. The participant must have 
an active signed consent for one of the above mentioned protocols on file for baseline examinations 
to occur. Baseline examinations will be performed as outlined in Appendix 2. Laboratory measures 
may be performed within 42 days of enrollment. Optical coherence tomography (OCT), color 
fundus photography and fluorescein angiography may be performed within seven days of the 
baseline visit. All other baseline examinations must occur on the day the participant reviews and 
signs this protocol’s consent form, unless specified in Appendix 2. Treatment with the IP 
(minocycline or placebo) cannot occur until the participant has reviewed and signed this protocol’s 
consent form. 
Potential participants from the BRC sites will be screened under this study protocol.  
The participant must have signed this protocols consent form for any study examinations to occur. 
For the BRC sites, it is expected that the baseline examinations can be completed in one clinic visit 
over one day. If the baseline examinations cannot be performed in one clinic visit over one day, it 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 15 
is acceptable that the baseline examinations be completed at subsequent clinic visits, if scheduled 
within fourteen days of the first visit. 
4.4 
Randomization, Masking and Unmasking 
After the participant is determined eligible and has completed the informed consent process, the 
group will be assigned based on a predetermined randomization schedule developed by the 
Coordinating Center. Randomization will be stratified by site. 
Randomization must occur on the same day as the initial administration of IP while the participant 
and the ophthalmologist are present and will not be permitted any time before.  
Participant eligibility must be confirmed before a participant is randomized. Participants will be 
randomized to one of two groups with equal probability of equal numbers of participants in each 
group: minocycline or placebo. Participants must continue to receive the same treatment regimen 
to which they were assigned for the duration of the study. 
All clinic staff and participants will be masked to group assignments. Only designated pharmacy 
personnel, select individuals at the Emmes Corporation, and the NEI Data and Safety Monitoring 
Committee (DSMC) will have access to the group assignments. 
Participants will be unmasked if deemed clinically necessary by the examining physician and if 
the study Principal Investigator (PI) and DSMC Chair are in agreement. In the case of a medical 
emergency, the examining or treating physician will have the final decision and unilateral right for 
unmasking. A request for unmasking, after approval by the PI and the DSMC Chair, will be made 
to the Coordinating Center personnel, who will inform the PI and the DSMC Chair of the group 
assignment. Attempts should be made to maintain the masking of the investigators prior to the 
study-wide unmasking. Unmasking will be recorded on an AE form. All instances of unmasking 
must be reported to the ICRRC, the CNS IRB and the DSMC. 
4.5 
Study Design and Procedures 
For the NEI Site: The study duration will be 24 months. During this period, participants will be 
instructed to take the IP (either placebo or minocycline 100 mg capsule) twice daily. The primary 
outcome will be assessed at Month 12, and secondary outcomes will be assessed at 6, 12, 18 and 24 
months. Visits will occur at baseline, and then monthly or as clinically indicated. The study will 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 16 
require a minimum of 25 appointments (baseline and Months 1-24). All appointments must be 
conducted within a window of ± seven days from the target day. The tests scheduled at each visit 
will be completed in one day. At each visit, the participant will undergo a review of systems and 
an assessment of safety variables. A complete ophthalmologic examination will be performed at 
each visit to measure outcome variables. 
During each clinic visit, participants will have their visual acuity measured and will undergo OCT 
testing to measure retinal thickness. 
For the BRC Sites: The study duration will be approximately 24 months. During this period, 
participants will be instructed to take the IP (either placebo or minocycline 100 mg capsule) twice 
daily. The primary outcome will be assessed at Month 12, and secondary outcomes will be assessed 
at 6, 12, 18 and 24 months. Visits will occur at baseline, and then monthly or as clinically indicated. 
The study will require a minimum of 26 appointments (baseline and Months 1-24 and safety 
follow-up). All appointments must be conducted within a window of ± seven days from the target 
day, except for the safety follow-up visit which must occur at least five days after the cessation of 
IP. The tests scheduled at each visit are expected to be completed in one day, with the exception 
of the Baseline visit, Month 12 visit and Month 24 visit. If the baseline examinations cannot be 
performed in one clinic visit over one day, it is acceptable that the baseline examinations be 
completed at subsequent clinic visits, if scheduled within fourteen days of the first visit. If the 
Month 12 and Month 24 examinations cannot be performed in one clinic visit over one day, it is 
acceptable that the examinations be completed at subsequent clinic visits, if scheduled within 
seven days of the first visit. At each visit, the participant will undergo a review of systems and an 
assessment of safety variables. A complete ophthalmologic examination will be performed at each 
visit (except for the safety follow-up visit) to measure outcome variables. If the Baseline visit, 
Month 12 visit, or Month 24 visit are conducted over more than one day, BCVA, OCT and 
microperimetry testing must be conducted on the day of the injection. 
During each study visit, with the exception of the Month 24 visit and safety follow-up visit at the 
BRC sites, IP will be dispensed to the participant unless the treatment is deemed to be “worsening” 
or to offer “no improvement,” and the participant and investigator decide to stop IP.  
An information sheet outlining instructions on taking the study medication and concomitant 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 17 
medications will be distributed to participants and discussed in detail by study personnel.  
They will be asked to inform any physician who is prescribing new medications that they are 
currently taking minocycline. In addition, the participants will be asked to inform a study team 
member if a new medication is prescribed to them. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 18 
Participant compliance with IP will be prompted through ongoing encouragements and reminders 
during study visits and scheduled and unscheduled telephone contacts. Compliance will be 
assessed by pill counts conducted during study visits and the participant’s pill diary.  
Once identified, occurrences in which the computed compliance rate between study visits falls 
below 50% will be reported as a protocol deviation to the CNS IRB within two weeks using PTMS. 
4.5.1 Treatment Prior to Month 3 
At baseline, the participant will receive an injection of 1.25mg bevacizumab, an anti-VEGF agent, 
and also start the randomized IP. At Months 1 and 2, the participant will again receive bevacizumab 
injections in the study eye and continue the randomized IP. 
4.5.2 Treatment Beginning at Month 3 
Visual acuity and macular edema will be evaluated at study visits to determine further treatment. 
Starting at Month 3 and at every visit thereafter, the following scenarios will be considered.  
(Also refer to Figure 1.) The participant will be reinjected with bevacizumab unless the participant 
meets the “improvement,” “worsening,” “new steady state” or “no improvement” criteria defined 
in Appendix 3. 
Scenario 1: If the participant meets the “improvement” criteria defined in Appendix 3, the 
participant will continue to take the IP, but the bevacizumab injection will be withheld at that visit. 
Scenario 2: If the participant meets the “worsening” criteria defined in Appendix 3, the participant 
will be offered any therapy available at the discretion of the treating investigator, including: 
a. Anti-VEGF Treatment 
b. Intravitreal or Periocular Steroid Injections 
Scenario 3: If the participant does not meet the “improvement” or “worsening” criteria, but meets 
the “new steady state” criteria defined when the central subfield thickness remains ≥ 300 microns 
on OCT but has not changed > 25 microns over the last three consecutive injections (also defined 
in Appendix 3), the treating investigator physician will have the discretion to hold bevacizumab 
injections until the OCT changes (worsens) by > 25 microns from this “new steady state” level. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 19 
At the Month 12 visit and at every visit thereafter, Scenarios 1, 2 and 3 will be considered as well 
as the following scenario, which allows for a study physician to determine whether there has been 
“no improvement” in the participant’s condition: 
Scenario 4: If the participant meets the “no improvement” criteria defined in Appendix 3, or if the 
investigator’s clinical impression is that there has been no improvement in the study eye, the 
participant will be offered therapy at the discretion of the treating investigator. The decision to  
re-inject the participant with bevacizumab (the anti-VEGF agent) will be made by the treating 
investigator after consulting with the participant. The decision to continue the IP will also be made 
by the treating investigator after consulting with the participant. 


MiCRVO 
 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 20 
Figure 1. Treatment Scenarios 
 
 
 
Enrollment = Month 0 
- Confirm eligibility 
- Review/sign consent form 
- Give bevacizumab injection 
- Randomize participant to 
investigational product 
Months 1, 2 
- Give bevacizumab injection  
- Dispense randomized 
investigational product to 
participant 
Is this visit Month 12 or after? 
no 
yes 
Does participant meet criteria 
for “no improvement?” 
- Treat participant at the 
discretion of treating investigator 
no 
- Dispense randomized 
investigational product 
- Hold bevacizumab 
injection 
- Treat participant at 
the discretion of 
treating investigator 
no 
Does the participant meet 
criteria for “improvement?” 
yes 
yes 
Does participant meet 
criteria for “worsening?” 
no 
yes 
Months 3 and thereafter 
- Consult decision tree to the 
right 
Does participant meet criteria for “new 
steady state?” 
yes 
-Dispense investigational 
product 
-Investigator physician discretion 
to hold bevacizumab injection 
no 
- Dispense randomized 
investigational product 
- Give bevacizumab 
injection


MiCRVO 
 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 21 
4.6 
Ocular and Systemic Evaluations 
Following is a detailed list of the study procedures. All of the study procedures, with the exception 
of the administration of the IP, are typical components of the clinical care required for a participant 
with macular edema secondary to CRVO. Examinations are performed at the study visits as 
indicated in the study flowsheet (Appendix 2). 
1. Dispense IP and provide an information sheet outlining instructions on taking IP and 
concomitant medications and pill diary 
2. Drug Accountability Review 
3. Evaluation for “improvement,” “worsening” and “no improvement” defined in  
Appendix 3 
4. Medical/Ophthalmic History 
5. Physical Examination 
6. Vital Signs 
7. Review of Systems 
8. Allergies Assessment 
9. Concomitant Medications Assessment 
10. Adverse Event Assessment 
11. Best-Corrected Visual Acuity (BCVA) and Manifest Refraction using Early Treatment 
Diabetic Retinopathy Study (ETDRS) Methods 
12. Slit Lamp Examination 
13. Dilated Fundus Examination 
14. Color Fundus Photography (CFP) 
15. Intraocular Pressure (IOP) 
16. Spectral Domain Optical Coherence Tomography (OCT) 
17. Microperimetry 
18. Fluorescein Angiogram (FA) 
19. Acute Care Panel1 
20. Hepatic Panel1 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 22 
21. Complete Blood Count (CBC)1 
22. Thyroid Function Test1,2  
23. Thyroid Palpation3 
24. Pregnancy Test for Women of Childbearing Potential (serum and urine)1, 4 (see Appendix 
1 for definition) 
1  All abnormal values or positive tests will be reported to the participant’s primary care 
physician, with the participant’s permission. 
2  Participants with abnormal thyroid function test results will be referred to an 
endocrinologist. 
3 Abnormal findings during a thyroid palpation will be followed by a referral to an 
endocrinologist. 
4 Applicable to the BRC sites only: A serum pregnancy test will be performed with  
24 hours prior to initiation of minocycline. After initiation of contraception, urine 
pregnancy tests will be conducted; however, a serum test will be performed anytime a 
urine test result creates doubt. 
If any medications need to be initiated or altered to address any change in lab values, or symptoms, 
the participant’s primary care doctor will be contacted, or the medical consultant team will be 
contacted to evaluate the participant and to prescribe the appropriate medications. 
4.6.1 Reporting of Expected Events 
It is anticipated that participants in this study will occasionally miss or fail to complete an assessment, 
procedure or study visit. These omissions will be considered expected events and not protocol 
deviations provided they are infrequent and do not include data needed to assess safety or the primary 
study outcome. If such an event is identified, the PI will submit a report to the IRB within two weeks 
using PTMS. 
Cumulative proportions of these missed events in the study population will be presented to the IRB 
annually. In addition, these rates will be calculated and monitored biannually by the DSMC. 
The following are considered deviations: 
 An individual misses more than 15% of the required study assessments/procedures, 
 An individual misses more than 15% of the required study visits, 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 23 
 An individual completes more than 15% of the required study visits outside of the visit 
window, 
 Collectively, participants missed more than 15% of a specific assessment/procedure, 
 Collectively, participants missed more than 15% of the required study visits, or 
 Collectively, participants complete more than 15% of the required visits outside the visit 
window. 
If the total number of expected items (study visits or study assessments/procedures) is less than or 
equal to 16, and two or more items are missing, a deviation will be reported. If the total number of 
items expected is greater than 16, and 15% or more items are missing, a deviation will be reported. 
The total number of items (study visits or study assessments/procedures) for an individual and 
collectively will be calculated cumulatively. If a protocol deviation (as defined above) is identified, 
the PI will submit a report to the IRB using PTMS. 
4.7 
Study and Concomitant Therapy 
4.7.1 Minocycline Formulation at Pine Pharmaceuticals 
Pine Pharmaceuticals (100 Colvin Woods Parkway #300, Tonawanda, New York) will supply the 
minocycline hydrochloride capsules for oral administration containing 100 mg of minocycline 
(NDC number 00591-5695-50, manufactured by Actavis Pharma, Inc.). Pine Pharmaceuticals will 
provide the pink opaque capsules to the NIH Pharmacy. 
4.7.2 Minocycline Formulation for BRC Sites 
At the BRC sites, minocycline hydrochloride capsules for oral administration containing the 
equivalent of 100 mg of minocycline will be investigated under European Clinical Trials Database 
(pending EudraCT submission to M.H.R.A.) For the BRC sites, the commercial licensed tablets 
will be overencapsulated by the BEH pharmacy. 
4.7.3 Placebo Formulation at Pine Pharmaceuticals 
Pine Pharmaceuticals will formulate and supply a placebo pill with inactive ingredients in a pink 
opaque capsule. The prepared capsules will be provided to the NIH Pharmacy. The placebo 
capsules are indistinguishable from the minocycline capsules used in this trial. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 24 
4.7.4 Placebo Formulation for BRC Sites 
The BEH pharmacy has formulated a placebo capsule with inactive ingredients. The placebo 
capsules are indistinguishable from the minocycline capsules used in this trial. 
4.7.5 Dosage, Administration and Storage 
Participants will be instructed to take the IP orally two times a day, once in the morning and once in 
the evening approximately 12 hours apart. The exception to this will occur on the day of the baseline 
visit. On the day of the baseline visit at which IP is dispensed, participants will take only the evening 
pill. Minocycline will be administered at an oral dose of 100 mg twice daily. Placebo pills contain 
no active ingredients. 
At the baseline and Months 1-23 study visits, a 37-day supply will be dispensed. Participants will 
be given a pill diary upon which to record the morning and evening doses of the IP. The IP should 
be stored at 15 – 30° C (59 - 86° F). It should be protected from light, moisture and excessive heat. 
Participants will be required to return their bottles of IP to each visit for pill counts for compliance 
monitoring. 
4.7.6 Concomitant Therapy 
If the study eye develops neovascularization warranting panretinal photocoagulation, the 
participant will withdraw from this study because it is known that panretinal photocoagulation 
laser can exacerbate macular edema. This could interfere with the interpretation of the study data 
(see exclusion criteria Section 3.2.2). 
The non-study eye will receive standard care treatment, as appropriate. 
4.8 
Investigational Product Accountability 
The pharmacy and/or unmasked site staff designated to receive IP are responsible for the 
accountability of all used and unused study IP. Adequate drug accountability records include 
documentation of all IP and supplies shipped, received, formulated, dispensed and returned to the 
pharmacy. Participants will be asked to complete a pill diary documenting that they took the IP. 
At each visit, participants will be responsible for the return of a completed pill diary and any 
unused study medication and supplies. The investigator/study staff will review the pill diary with 
the participant for completeness and accuracy, document the number of returned pills and return 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 25 
the unused study medication and supplies to the appropriate pharmacy. Each pharmacy will 
destroy unused IP and supplies following reconciliation by the Coordinating Center. 
4.9 
Follow-up/Termination Procedures 
At the conclusion of the study, the participants will no longer be able to receive the IP under this 
protocol. 
At the NEI, follow-up care will be arranged with an outside ophthalmologist or the participant will 
continue to be seen at the NIH under another protocol, if available, and if the participant is eligible. 
The participants and their physicians, with written consent, will be informed of their disease status 
during this study. Clinical data obtained during participation may be shared with the participants 
and, with written permission from the participants, their private physicians. Results from the 
overall study will be listed on http://www.clinicaltrials.gov once the data have been analyzed. 
4.10 
Storage of Samples and Data 
No samples will be stored for this study. At the NEI, the clinical data will be stored in the NEI’s 
electronic medical record system (EMR), The Emmes Corporation’s database and the Clinical 
Research Information System (CRIS). At the BRC sites, the clinical data will be stored in The 
Emmes Corporation’s database. Some of the baseline data for the NEI may be obtained under the 
NEI screening or evaluation and treatment protocols. 
5.0 
RISKS/DISCOMFORTS 
There are risks associated with the procedures required for participants in this study.  
However, these are all standard procedures that are performed as part of a normal eye and medical 
examination. Some of the discomforts associated with the ocular examination include the 
following: 
1. Dilating drops or anesthetic drops may sting. They can cause an allergic reaction, or if 
contaminated, can cause an infection, but neither of these problems is very likely to occur. 
Dilating drops can also cause a sudden increase of pressure (acute glaucoma) in eyes that 
are already predisposed to develop this condition. There is little risk of glaucoma being 
triggered in this way, but if it is, treatment is available. The participant’s intraocular 
pressure will be obtained at each ophthalmic examination to determine whether there is an 
increased risk of developing glaucoma. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 26 
2. Color fundus photographs involve a bright flash to take pictures of the retina. This brief 
flash may cause temporary discomfort, but it does not damage the eye. 
3. In rare instances, the cornea may be scratched during measurement of intraocular pressure 
or use of a funduscopic contact lens. A corneal abrasion of this sort may be painful, but it 
heals quickly with no lasting effects. 
4. The fluorescein dye used in fluorescein angiography can make a participant’s skin turn 
yellow for several hours. This yellow color is transient and usually disappears in one day. 
Because the dye undergoes renal excretion, the participant’s urine will turn dark orange for 
up to 24 hours after the examination. The study team will educate the participant regarding 
this urine color change. Some participants may be slightly nauseated during the 
examination, but their nausea usually lasts only a few seconds. If the dye extravasates 
during the injection, the skin around the injection site may feel mildly uncomfortable or 
become yellow. The discomfort usually lasts only a few minutes, and the yellow color fades 
in a few days. There is a chance of ecchymosis at the site of injection and a remote 
possibility of cellulitis from the needle track. 
In rare cases, participants may have an allergic reaction to the dye. Treatment typically 
consists of an oral antihistamine medication, but may require intravenous antihistamine 
administration if the symptoms are severe. Very rarely (less than one in one million 
people), a participant experiences anaphylaxis. This would be treated immediately by 
trained personnel with medications or, if necessary, intubation. 
5. OCT and microperimetry are non-invasive tests used to document and analyze retinal 
pathology. Neither test has any known medical risks. 
Possible discomforts associated with non-ocular examinations include: 
1. Blood draws can cause discomfort and bleeding/bruising at the site of venous puncture. 
There is a remote risk of fainting or local infection. If any of these conditions arise, they 
will be treated. 
2. The medical/ophthalmic history, vital signs, review of systems and pregnancy testing entail 
no medical risk. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 27 
5.1 
Intravitreal Bevacizumab Risks 
The following data on the complications of intravitreal injections of bevacizumab were taken from 
a publication on the subject.43 The following event rates were observed as described in Table 1. 
There is no statistically significant difference in event rates between bevacizumab and ranibizumab 
in any of these categories listed below. Risks related to the mechanical injection include 
endophthalmitis, retinal tears, vitreous hemorrhage, intraocular pressure elevation and lens 
damage. Risks related to the pharmacological agent include uveitis and endophthalmitis. 
Table 1. 
Comparison of Ocular Adverse Events Occurred Among Patients Treated 
with Intravitreal Bevacizumab versus Ranibizumab 
Ocular Adverse Event 
Bevacizumab  
(n = 1,275) 
(%) 
Ranibizumab 
(n = 725) 
(%) 
P 
Retinal detachment  
1 (0.08) 
0 
1.0 
Injection-site redness 
821 (64.39) 
474 (65.38) 
>0.6 
Corneal abrasion 
6 (0.47) 
3 (0.41) 
1.0 
Anterior uveitis 
20 (1.57) 
10 (1.38) 
>0.6 
Posterior or anterior-posterior 
uveitis 
5 (0.39) 
3 (0.41) 
1.0 
Subconjuctival hemorrhage 
125 (9.80) 
75 (10.35) 
>0.6 
Subconjuctival hemorrhage  
(> 1 quadrant)
6 (0.47) 
5 (0.69) 
>0.5 
 
5.2 
Investigational Product Risks 
5.2.1 Minocycline-related 
Due to oral minocycline’s virtually complete absorption, side effects to the lower bowel, 
particularly diarrhea, have been infrequent. The following adverse reactions have been observed 
in patients receiving tetracyclines. 
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, 
pancreatitis, inflammatory lesions (with monilial over growth) in anogenital region and increases 
in liver enzymes. Rarely, hepatitis and liver failure have been reported. Rare instances of 
esophagitis and esophageal ulcerations have been reported in patients taking the tetracycline-class 
antibiotics in capsule and tablet form. Most of these patients took the medication immediately 
before going to bed. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 28 
Skin: Maculopapular and erythematous rashes. Exfoliative dermatitis has been reported but is 
uncommon. Fixed drug eruptions, including balanitis, have been rarely reported.  
Erythema 
multiforme 
and 
rarely 
Stevens-Johnson 
syndrome 
have 
been 
reported.  
Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some 
individuals taking tetracyclines. This has been reported with minocycline. Pigmentation of the skin 
and mucous membranes has been reported. 
Renal toxicity: Elevations in BUN have been reported and are apparently dose related. While this 
is not a problem in those with normal renal function, in patients with significantly impaired 
function, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia and 
acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive 
systemic accumulations of the drug and possible liver toxicity. 
Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, 
anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus and rarely 
pulmonary infiltrates with eosinophilia have been reported. A transient lupus-like syndrome has 
also been reported. 
Blood: Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported. 
Central Nervous System: Central nervous side effects including light-headedness, dizziness, or 
vertigo have been reported with minocycline therapy. Serious neurologic events reported include 
bulging fontanels in infants and benign intracranial hypertension (Pseudotumor cerebri) in adults. 
Headache and blurred vision have also been reported. 
Other: When given over prolonged periods, tetracyclines have been reported to produce  
brown-black microscopic discoloration of the thyroid glands. Very rare cases of abnormal thyroid 
function have been reported. Thyroid cancer has been reported in the post-marketing setting in 
association with minocycline products. Decreased hearing has been rarely reported in patients on 
minocycline hydrochloride. Tooth discoloration in children less than eight years of age and also, 
rarely, in adults has been reported. Use is not recommended for individuals of either gender 
attempting child conception. There is a risk of impaired spermatogenesis. Because tetracycline can 
reduce the amount of beneficial forms of bacteria in the body, participants will be counseled to 
include probiotics in their diet while participating in the study. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 29 
Pregnant and Nursing Women: Minocycline is in Pregnancy Category D and is excreted in human 
milk. Minocycline can cause fetal harm when administered to a pregnant woman. The use of drugs 
of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood 
to the age of eight years) may cause permanent discoloration of the teeth (yellow-grey-brown). 
5.2.2 Drug Interaction-related 
Because tetracyclines have been shown to depress plasma prothrombin activity, participants who 
are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to 
avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of tetracyclines is 
impaired by antacids containing aluminum, calcium, or magnesium, and preparations that contain 
iron. The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal 
renal toxicity. Concurrent use of tetracyclines with oral contraceptives may render oral 
contraceptives less effective. 
5.2.3 Placebo-related 
There are no medical risks associated with the placebo capsules. 
6.0 
Participant Monitoring 
Participants will be monitored during all study visits for AEs by the study investigators. At each 
visit, the participant will be asked about any new ocular or systemic symptoms including rashes, 
hospitalizations or new/changed medications. General and ophthalmic assessments will be 
performed according to Appendix 2. Stopping guidelines for individual participants and the entire 
study are outlined below. 
6.1 
Individual Withdrawal Criteria 
Participants may choose to withdraw from this study for any reason at any time without penalty, 
without loss of benefits, and without prohibition from enrolling in other clinical protocols. 
Participants may stop the study at any time. The investigators will ask all study participants to 
continue to return for study visits even if they stop using the IP. However, participants are free to 
withdraw from the study at any time. Also, investigators may withdraw a participant from IP if the 
investigator determines that the study is not in the participant’s best interest. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 30 
Reasons for participant discontinuation may include, but are not limited to, the following: 
 Investigator determination that it is not in the best medical interest of the participant to 
continue participation; 
 Findings during the course of the trial that may affect willingness to participate; 
 Participant requires additional medicines or intravitreal injections that may interfere with 
the IP; 
 Serious suspected adverse reaction; 
 VA loss of  15 letters from baseline; 
 Any other safety concerns; 
 Inability to keep study visits or to comply with study requirements; or 
 Participant requires ocular surgery which cannot safely be postponed until the end of the 
study. 
Discontinuation of IP does not require participant withdrawal from the study. If the participant 
agrees to continue in the study after discontinuing IP, s/he will continue to return for his/her 
subsequent study visits and undergo the required examinations. Otherwise, the participant will exit 
the study and continue his/her ophthalmic care either with an outside ophthalmologist or at the 
NEI. Participants will be monitored by study investigators and clinical staff at each visit to the 
clinic. 
6.2 
Pregnancy Monitoring 
If the staff becomes aware that a female study participant has become pregnant during the study, 
the investigator will advise the participant to stop taking the IP immediately. The investigator 
and participant will determine whether to continue any remaining study visits or to exit the study. 
If the staff becomes aware that a male study participant has impregnated his partner during the 
study, the investigator will remind the participant of the potential risks to the unborn fetus. 
For the NEI site, in either case of reported pregnancy, the NEI participant (and/or partner) will 
be referred to the NIH OB/GYN consultation service for evaluation and counseling.  
The investigator must follow the participant (or partner) until the pregnancy outcome. The data 
must be recorded on the Confirmed Pregnancy & Outcome case report form, which is also 
reported to the Coordinating Center. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 31 
7.0 
OUTCOME MEASURES 
7.1 
Primary Outcome 
The primary outcome is the difference in mean change of BCVA, as measured in ETDRS letters, 
between the minocycline and placebo groups in the study eye at 12 months compared to baseline. 
7.2 
Secondary Outcomes 
Secondary outcomes include the difference between the minocycline and placebo groups in the: 
 Number of bevacizumab injections from baseline to 12 months and from baseline to 
24 months, 
 Changes in mean macular sensitivity as measured by microperimetry at 3, 6, 12, 18 and 24 
months compared to baseline, 
 Mean change in the ETDRS BCVA in the study eye at 24 months compared to baseline, 
 Changes in retinal thickness as measured by OCT at 6, 12, 18 and 24 months compared to 
baseline, 
 Number of participants improving > 1 logOCT scale step at 12 and 24 months compared 
to baseline, 
 Changes in fluid leakage in the macula as demonstrated by fluorescein angiography at  
12 and 24 months compared to baseline. 
Also, a decrease of ≥ 1-step on the logOCT scale, where Change in logOCT = log (follow-up 
thickness/300) – log(baseline thickness/300) is considered clinically significant.42 A one-step 
decrease is equivalent to at least a 20% improvement of central macular thickness and represents 
greater than twice the variability of retinal thickness measurements (approximately 25-30 
microns). Table 2 presents examples of OCT measurements with their corresponding LogScore, 
where LogScore = 10xlogOCT. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 32 
Table 2. OCT and Corresponding LogScores42 
LogScore 
OCT (µm) 
0 
300 
0.5 
337 
1 
378 
1.5 
424 
2 
475 
2.5 
533 
3 
599 
3.5 
672 
4 
754 
4.5 
846 
5 
949 
5.5 
1064 
6 
1194 
6.5 
1340 
7.3 
Safety Outcomes 
Safety outcomes will be the number and severity of systemic and ocular toxicities and AEs.  
The number of participants withdrawn from the study therapy due to vision loss or AEs and the 
number of participants deemed to have worsening disease will also contribute to the assessment of 
safety. 
8.0 
STATISTICAL ANALYSIS 
As this is a pilot study, analyses will be primarily descriptive and by eye. Additionally, all 
exploratory analyses carried out may be stratified by site. No formal sample size calculation has 
been performed. The accrual ceiling for this study is 20 participants (10 per group) with a minimum 
of 10 participants (five per group). This number was selected to obtain at least five participants in 
each group reaching the final study visit in order to obtain preliminary data to potentially support 
a larger trial if promising results are revealed. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 33 
BCVA will be evaluated at each scheduled visit, and the primary outcome is defined as the 
difference between groups (those randomized to placebo and those randomized to minocycline) in 
mean change in BCVA in the study eye at 12 months compared to baseline. This study will be 
unable to determine whether there is a statistically significant difference in mean change in BCVA 
between placebo and minoycline groups. Difference in mean change (± standard deviation) in 
BCVA across the two groups will be presented, and interval estimates of mean change in BCVA 
will also be constructed. Exploratory nonparametric statistical analyses will be conducted where 
appropriate. Mean (per group) and individual BCVA will be plotted against time. 
The number of bevacizumab injections required by participants will be assessed as a secondary 
outcome. The number of bevacizumab injections will be summarized for each participant from 
baseline to 12 months and from baseline to 24 months in each group (those randomized to 
minocycline versus placebo) and the means will be compared. 
Changes in mean macular sensitivity as measured by microperimetry will also be assessed as a 
secondary outcome at months 3, 6, 12, 18 and 24 as compared to baseline. A number of recent 
publications have demonstrated the usefulness of microperimetry in assessing macular function in 
vein occlusions.44-55 In addition, some of these studies have found that retinal sensitivity as 
measured by microperimetry correlates more precisely with macular edema thickness 
measurements than with visual acuity measurements.51-52 
Additional secondary outcome measures include changes in retinal thickness in the study eye as 
measured by OCT. Individual and mean changes in retinal thickness will be summarized and 
plotted against time. Other secondary outcomes include change in BCVA in the study eye at 12 
and 24 months compared with baseline, proportion of participants improving ≥ 1 logOCT scale 
step, and change in fluid leakage in the macula of the study eye as demonstrated by fluorescein 
angiography at 12 and 24 months compared to baseline. In general, changes in BCVA, changes in 
retinal thickness, and changes in fluid leakage in the macula will be monitored throughout the 
study period in both the study and fellow eyes. Analyses pertaining to these outcomes will be 
descriptive and will include tabulations with point and interval estimates and plots of outcome 
values over the study period for all participants. Exploratory nonparametric statistical analyses will 
be conducted where appropriate. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 34 
Participants who were exposed to recent (< three months) systemic steroid or systemic  
anti-VEGF prior to enrolling will also be analyzed separately to assess for any possible 
confounding effects for treatment benefit. Safety outcomes, including the number and severity of 
systemic and ocular toxicities and AEs will be summarized by severity, type and assessed 
relatedness to the IP throughout the study period. The number of participants withdrawn from the 
IP due to vision loss or AEs and the number of participants deemed to have worsening disease will 
also be summarized. Worsening disease is defined as loss of 15 or more ETDRS letters of vision 
compared to baseline OR a ≥ 1-step increase in the logOCT scale. These safety analyses will use 
data of all participants who were exposed to IP regardless of adherence to the protocol. 
Participants’ compliance with IP administration will be assessed through capsule counts during 
study visits. If study IP compliance falls below 80% of the level prescribed for any participant, the 
participant will be queried by the site about the reasons for decreased compliance and counseled 
on the importance of compliance for study integrity. The level of compliance will be reported to 
the IRB on annual review and taken into account in the analyses of study outcomes. When IP 
compliance cannot be determined for a participant during any visit due to missing capsule counts, 
IP compliance will be imputed by taking the median of all available capsule counts recorded at 
previous study visits. 
9.0 
HUMAN PARTICIPANTS PROTECTION 
9.1 
Equitability 
Accrual for this study will be equitable among participants with RVOs meeting the enrollment 
criteria. All participants will have received the standard care therapy prior to enrollment. 
9.1.1 Justification for Exclusion of Children 
Children are not eligible for this study as minocycline has not been fully studied in children and is 
not indicated for use in children. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 35 
9.1.2 Justification for Exclusion of Pregnant or Lactating Women 
Pregnant or lactating women are not eligible for this study because of the known and unknown 
risks of minocycline. One of the known risks of minocycline is that it can cause permanent 
discoloration of the teeth (yellow-grey-brown) of a fetus when given to a pregnant woman during 
the last half of pregnancy. Minocycline also passes into breast milk and can cause permanent 
discoloration of the teeth of a nursing infant. Given the known and unknown effects on pregnancy 
outcomes, two forms (one form for BRC sites) of contraception will be required for female 
participants of childbearing potential (see Appendix 1 for definition). In addition, female 
participants of childbearing potential will undergo urine pregnancy tests throughout the study. 
9.2 
Qualifications of Investigators 
The following physicians who will be treating the participants are experienced in caring for 
patients with RVOs. In addition, they are experienced in conducting studies similar to this protocol. 
Credentialed NEI staff physicians may also conduct procedures under the direction of these 
investigators. 
The NEI PI has verified that all individuals working on this protocol at the NEI site required to 
take HRPP training under OHSRP SOP 25 (Training requirements for the NIH Human Research 
Protections Program) have completed all required training. 
The BRC site PIs have verified that all individuals working on this protocol at their site are 
sufficiently trained to complete the tasks delegated to them on the study Authorized Staff Signature 
log. 
Catherine Cukras, MD, PhD is the PI with the ability to obtain informed consent. She is responsible 
for 
obtaining 
medical 
history, 
performing 
scheduled 
ophthalmic 
study 
visits, 
dispensing/administering medication, maintaining regulatory documentation, submitting IRB 
materials, generating clinical source documents, resolving data queries and overseeing the 
protocol. Dr. Cukras is currently a staff clinician at NEI. She completed the medical retina clinical 
fellowship at NEI and has mentored medical students in the NEI retina clinic. Dr. Cukras currently 
serves as the PI on a protocol investigating minocycline for the treatment of macular edema.  
She has also served as an Associate Investigator on other clinical research studies on related ocular 
diseases. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 36 
Clare Bailey, MD is the PI for the Bristol Eye Hospital with the ability to obtain informed consent 
at the UK sites. She is responsible for obtaining medical history, performing scheduled ophthalmic 
study visits, administering and dispensing medication, completing regulatory documentation and 
regulatory submissions, generating clinical source documents, resolving data queries and the 
overall oversight of the protocol for the BEH site. Dr. Bailey is a consultant ophthalmologist in 
medical and surgical retina at the BEH and a member of the Royal College of Ophthalmologists. 
Bishwanath Pal, MBBS, MS, Ophth, FRCOphth, FRCSEdin, is the PI for Moorfields Eye Hospital 
with the ability to obtain informed consent from patients at the MEH site. He is responsible for 
obtaining medical history, performing scheduled ophthalmic study visits, administering and 
dispensing medication, completing, generating clinical source documents, resolving data queries 
and the overall oversight of the protocol for the Moorfields site. Dr. Pal is a consultant 
ophthalmologist in medical retina at Moorfields Eye Hospital and a member of the Royal College 
of Ophthalmologists. 
Wai Wong, MD, PhD is the Lead Associate Investigator with the ability to obtain informed 
consent. He is responsible for obtaining medical history, performing scheduled ophthalmic study 
visits, dispensing/administering medication and generating clinical source documents. Dr. Wong 
is a staff clinician and the head of the unit of neuron-glial interactions in retinal diseases at NEI. 
Dr. Wong currently serves as an Associate Investigator on another protocol for the treatment of 
macular edema targeting microglia. Dr. Wong has clinical experience and conducted research 
studies on related ocular diseases as a Principal and Associate Investigator. 
Emily Chew, MD is an Associate Investigator and Accountable Investigator with the ability to 
obtain informed consent. She is responsible for obtaining medical history, performing scheduled 
ophthalmic study visits, dispensing/administering medication and generating clinical source 
documents. Dr. Chew is the deputy clinical director (CD) and director of the medical retina 
fellowship program at NEI. Dr. Chew is on the editorial board of a diabetic journal and serves on 
several committees focused on the care of patients with diabetes. Dr. Chew has conducted 
numerous research studies as a Principal and Associate Investigator on related ocular diseases. 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 37 
Henry Wiley, MD is an Associate Investigator with the ability to obtain informed consent. He is 
responsible for obtaining medical history, performing scheduled ophthalmic study visits, 
dispensing/administering medication and generating clinical source documents. Dr. Wiley has 
clinical experience and has conducted research studies as a Principal and Associate Investigator 
on related ocular diseases. 
Alexander Kaplan, MD, Christopher Hwang, MD and Munir Iqbal, MD, FRCSC are Associate 
Investigators with the ability to obtain informed consent. They are responsible for obtaining 
medical history, performing scheduled ophthalmic study visits, dispensing/administering 
medication and generating clinical source documents. They are currently clinical fellows at the 
NEI. 
Angela Kibiy, MPH, BSN, RN is an Associate Investigator and the Research Contact without the 
ability to obtain informed consent. She is responsible for providing assistance to the PI with study 
procedures, generating clinical source documents, entering data and resolving data queries.  
Ms. Kibiy has been involved in clinical research studies on ocular diseases as an Associate 
Investigator and primary study coordinator/research contact. 
Awilda V. Holland, DNP, MSHSc, RN, CCRP is an Associate Investigator and back-up 
coordinator without the ability to obtain informed consent. She is responsible for providing 
assistance to the PI with study procedures, generating clinical source documents, entering data and 
resolving data queries. Dr. Holland is the NEI Clinical Trials Coordinating Section Chief and has 
been involved in clinical research studies on ocular diseases. 
Prior to screening or enrolling potential participants, the PI will verify all individuals working on 
this protocol have met the following training and certification requirements as applicable to their 
indicated role: 
9.2.1 Professional Licensure 
Physicians must provide evidence of current medical licensure applicable to the study location(s) 
if they are practicing medicine and undertake to diagnose and/or treat participants (including 
administration of the IP) in this study. A physician who is a site PI must also provide satisfactory 
evidence of ophthalmology training before study initiation. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 38 
10.0 
ANTICIPATED BENEFITS 
During this study, all participants will be eligible to receive intravitreal bevacizumab (Avastin®, 
an anti-VEGF agent. Additionally, participants who are randomized to minocycline may benefit 
directly from this study, as we hypothesize that minocycline may result in resolution or reduction 
of macular edema or improved visual acuity or need for fewer intravitreal bevacizumab injections. 
The study will also lead to generalizable knowledge regarding macular edema associated with 
CRVO. 
11.0 
CLASSIFICATION OF RISK 
Risk is classified as more than minimal risk. The risks will be minimized with careful monitoring and 
are reasonable given that the participants are experiencing visual loss due to CRVO. 
12.0 
CONSENT DOCUMENTS AND PROCESS 
Applicable study investigators with consenting privileges will obtain informed consent. All NIH 
study investigators obtaining informed consent have completed the National Institute of Mental 
Health (NIMH) Human Subject’s Protection Unit (HSPU) “Elements of Successful Informed 
Consent” training. All participants will receive a verbal explanation in terms suited to their 
comprehension of the purposes, procedures and potential risks of the study. The participants must 
have the ability to understand and sign an informed consent form, which must be signed prior to 
enrollment. The participants will have an opportunity to carefully review the consent and ask 
questions regarding this study prior to signing and they will be informed that they may withdraw 
from the study at any time without penalty to themselves or benefits lost. 
If the participant requires the consent to be in larger font in order to read it well, this will be 
provided. If participants are visually impaired to the point of being unable to read the consent, they 
can take the consent back with them to read it over with a family member or with the use of 
magnifying devices. If the participant chooses, the investigator can also read the consent verbatim 
to the participant and answer any questions that may arise. 
An investigator present during the consent process will document the consent process in the 
participant’s medical record. A signed copy of the informed consent form will be provided to the 
participant to take home. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 39 
12.1 
Unanticipated Enrollment of Non-English Speaking Participants at the NEI 
If a non-English speaking participant is eligible for enrollment at the NIH Clinical Center (CC), 
the participant will be provided with the CC Short Written Consent Form for Non-English 
Speaking Research Subjects in the participant’s native language and a verbal explanation of the 
purpose, procedures and risks of the study. The IRB-approved English consent form will serve as 
basis for the verbal explanation of the study. The investigator will obtain an interpreter unless the 
investigator is fluent in the prospective participant’s language. Preferably, the interpreter will be 
someone who is not related to the participant (i.e., not a family member). Interpreters provided by 
the CC will be used whenever possible. The interpreters will interpret the IRB-approved English 
consent form and facilitate discussion between the participant and investigator. 
The IRB-approved English consent form will be signed by the investigator obtaining consent and 
a witness to the oral presentation. The CC Short Written Consent Form will be signed by the 
participant and a witness who observed the presentation of information. The interpreter may sign 
the consent document as the witness and, in this case, will note “Interpreter” with his/her signature. 
If not also serving as the witness, the interpreter will be separately identified on the short form in 
the space provided. A copy of both signed forms (the long form serving as the script and the short 
form) will be provided to the participant. The short form process, including the use of an 
interpreter, will be documented in the medical record in accordance with NIH policy. 
All instances of use of the CC Short Written Consent Form will be reported to the IRB at the time 
of annual review. If the CC Short Written Consent Form is used three times or more for the same 
language within an IRB approval period, this will be reported to the IRB immediately. 
Interpreters will also be present for other protocol procedures as necessary. 
13.0 
DATA AND SAFETY MONITORING 
The NEI Data and Safety Monitoring Committee (DSMC) is responsible for monitoring data and 
safety, and will exercise oversight of the clinical investigation independently from the study 
investigators. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 40 
13.1 
Coordinating Center 
The Emmes Corporation has been assigned as the coordinating center for this trial to conduct data 
collection, protocol monitoring, data analysis and reporting. The coordinating center provides 
routine monitoring of study participants’ data. Monitoring visits will occur on a schedule 
depending on the status of the study. More frequent monitoring visits will be performed at the 
beginning of the study when enrollment is open. Monitoring will decrease as enrollment closes 
and as participant follow-up continues. The protocol monitor will monitor documentation for the 
informed consent process. In addition, the protocol monitor will review source documentation for 
the data collected throughout the trial to ensure that the data points are collected and reported. 
Communications between the investigational site and the Coordinating Center will be maintained 
through regular telephone and e-mail contacts between the Coordinating Center Protocol Monitor 
and the site PI and/or Coordinator. Substantive communications must be maintained both at the 
site and at the Coordinating Center containing the date and a summary of communications where 
instructions are given or received, an interpretation of protocol requirements is made, 
recommendations for corrections to study documentation are made, or where the reporting of 
possible AEs is discussed. 
Although the Coordinating Center advises the NEI CD and PI on data and statistical activities, the 
Coordinating Center staff does not have direct access to or interaction with participants. 
13.2 
Data and Safety Monitoring Committee 
The NEI DSMC is responsible for reviewing and approving the study design and, as appropriate, 
recommending design changes. In addition, the DSMC assesses study data with particular 
consideration of participant safety. The DSMC will convene prior to the initiation of the trial to 
review the protocol. Emmes will provide accumulated data from all study sites to the NEI DSMC 
for review. The Committee will review accumulated data on a biannual basis, but will convene ad 
hoc meetings to address any significant problems related to participant safety brought to its 
attention by any study participant or investigator. The Committee will review the accumulated data 
and consider whether a protocol modification is necessary and approve protocol modifications.  
If changes in protocol are indicated, recommendations will be made to the NEI Director and 
Clinical Center Director who will consider and act on such recommendations in a timely manner. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 41 
All protocol amendments must be reviewed and approved by the NEI DSMC prior to submission 
to the IRB. 
13.3 
Criteria for Stopping the Study 
The DSMC may recommend temporarily suspending or closing enrollment, or stopping the study 
at any time due to safety concerns, demonstration of efficacy or lack of efficacy, or slow 
recruitment. Criteria for stopping the study include the following: 
 A sufficiently large number of dropouts occurs as to make the trial likely to be 
uninformative; 
 A participant experiences a drop in BCVA in the study eye of  30 letters from baseline 
attributed to the IP; 
 A participant experiences a serious adverse event (SAE), drug reaction or complication, 
whether attributed to the IP or not, which has an impact on visual function or any other 
body system or precludes continuation of the IP. This would include the development of 
hypersensitization, allergic responses or other potentially serious drug reactions to 
medications required by the protocol. 
Following premature IP discontinuation, not due to an AE, participants will continue to be 
followed as per the protocol. 
14.0 
QUALITY ASSURANCE 
The NEI and Emmes maintain quality control by adhering to standard operating procedures  
(NEI QA program and NEIS standard operating procedures). These procedures cover the full 
protocol cycle beginning with staff credentialing and training, and protocol development and 
approval, through database development, data collection, monitoring and analysis, and finally 
manuscript preparation at the conclusion of the study. Data quality assurance is of the utmost 
importance to the NEI and Emmes. The two groups use a quality assurance system that relies on 
real-time data checks and reports throughout the course of a study to ensure the accuracy of 
information. This system is a secure and confidential data management system that stores data and 
provides quality assurance and reporting. Emmes has developed a number of routine reports 
specifically designed for monitors (e.g., listings of SAEs, etc.). 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 42 
Additionally, Emmes has developed summary reports of discrepancies, as well as reports of the 
exceptions databases, which include requests and reasons for exceptions. The results of the reports 
are communicated back to site staff, and, along with protocol compliance issues, to the DSMC (if 
applicable). 
Following the monitoring plan for this study, Emmes will perform monitoring activities, including 
on-site audits, review of database entries and the resolution of study issues. In addition to 
monitoring, Emmes performs various detailed automated and manual data quality checks.  
The results from these checks and any protocol compliance issues are communicated back to site 
staff and to the NEI Project Officer, NEI CD and applicable regulatory bodies. 
15.0 
REPORTING OF UNANTICIPATED PROBLEMS, ADVERSE EVENTS AND PROTOCOL 
DEVIATIONS 
The PI is responsible for detecting, documenting, and reporting unanticipated problems, AEs, 
including SAEs, and deviations in accordance with NIH policy, IRB requirements, and federal 
regulations. For the BRC sites, site PI is responsible for detecting, documenting, and reporting 
unanticipated problems, AEs, including SAEs, and deviations, occurring at their site.  
Relatedness to the research of all SAEs will be determined by the PI in consultation with the CD. 
Additionally, both the Sponsor and Investigator will report AEs (SAEs/SUSARs) from the sites in 
accordance with the European Directive 2001/20/EC. SAEs must be reported to the Sponsor by 
the Investigators within 24 hours of awareness. Non-SAEs that are expected as part of the natural 
history of the underlying disease will be summarized at the time of annual review to the IRB. 
Serious unanticipated problems, SAEs (including deaths) that are not unanticipated problems, and 
serious protocol deviations at the NIH will be reported to the CNS IRB and CD as soon as possible 
and in writing not more than seven days after the PI first learns of the event, unless immediate 
reporting is waived for specific SAEs as noted below. Not serious unanticipated problems and not 
serious deviations at the NIH will be reported to the CNS IRB and CD as soon as possible and in 
writing on the NIH Problem Report Form not more than 14 days after the PI first learns of the 
event. Written reports will be submitted in PTMS. For the BRC sites, the site PI is responsible for 
reporting events, including SAEs and protocol deviations to Emmes and the Sponsor, and then 
further reporting to regulatory authorities if reporting requirements are met. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 43 
All unanticipated problems, SAEs, and protocol deviations at the BRC sites will be monitored and 
reported per local regulations. These events will be reported to the NEI DSMC and unanticipated 
problems will be reported to the CNS IRB in the timeframes specified above. 
All AEs, deviations, and unanticipated problems will be summarized and reported to the CNS IRB 
at the time of Continuing Review. 
16.0 
ALTERNATIVE THERAPIES 
Alternatives to participation include further repeat treatment with intraocular injections of  
anti-VEGF agents such as bevacizumab (Avastin®) or ranibizumab (Lucentis®) without 
randomization to minocycline or placebo. Ranibizumab (Lucentis®) recently has been 
demonstrated to improve vision and edema, but the durability of the injections remains unknown. 
Other alternatives include the use of periocular and intraocular corticosteroids. Another approach 
would be observation. Other therapies have been administered with varying rates of success.  
All of these options are associated with significant side effects and complications if the treatment 
is extended and increased. Participants can alternatively receive minocycline outside of the study 
if prescribed off-label by their own physician. 
17.0 
PRIVACY 
All research activities will be conducted in as private a setting as possible. 
18.0 
CONFIDENTIALITY 
No blood, tissue or other samples will be stored in this study. All medical records will be kept 
confidential and will only be reviewed by the participating investigators. Data will be kept in 
password-protected computers held at the NEI and the Coordinating Center. Only study 
investigators and authorized Coordinating Center staff will have access to the study data.  
The participants’ names will not appear on any of the data forms reported to the Coordinating 
Center. A unique identifier will identify the participant if their information is shared with the 
Coordinating Center for research purposes. The participants’ names will not appear in any 
publication of the study results. Participants’ personal information will be kept as private as 
possible. However, records can be inspected by organizations for quality assurance and data 
analysis. Potential inspectors include the members of the FDA, IRB, DSMC and the Coordinating 
Center. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 44 
19.0 
CONFLICT OF INTEREST 
The NIH guidelines were distributed to all the investigators, and none of the investigators had any 
conflicts of interest. 
20.0 
TECHNOLOGY TRANSFER 
There are no technology transfer agreements for this study. 
21.0 
RESEARCH AND TRAVEL COMPENSATION 
For this study, there is no compensation for participation. This protocol does not include 
reimbursement for travel and subsistence. Participants needing financial assistance will be able to 
receive supplemental reimbursement based upon need. Requests for supplemental reimbursement 
will be evaluated on a case-by-case basis for valid financial and/or medical need through a 
standardized process. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 45 
22.0 
References 
1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in 
Australia. The Blue Mountains Eye Study. Archives of ophthalmology 1996; 114(10): 1243-
1247. 
2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the 
Beaver Dam Eye Study. Transactions of the American Ophthalmological Society 2000; 98: 
133-141; discussion 141-133. 
3. Brown DM, Campochiaro PA, Singh RP et al. Ranibizumab for macular edema following 
central retinal vein occlusion: six-month primary end point results of a phase III study. 
Ophthalmology; 117(6): 1124-1133 e1121. 
4. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: Basic 
concepts, clinical features and management. Progress in retinal and eye research 2008. 
5. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-alpha in 
retinal glial cells: implications for retinal neovascularization during post-ischemic 
inflammation. Graefe's archive for clinical and experimental ophthalmology = Albrecht von 
Graefes Archiv fur klinische und experimentelle Ophthalmologie 2004; 242(5): 409-413. 
6. Noma H, Funatsu H, Yamasaki M et al. Pathogenesis of macular edema with branch retinal 
vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. 
American journal of ophthalmology 2005; 140(2): 256-261. 
7. Bek T. Capillary closure secondary to retinal vein occlusion. A morphological, 
histopathological, and immunohistochemical study. Acta ophthalmologica Scandinavica 1998; 
76(6): 643-648. 
8. Antonetti DA, Barber AJ, Bronson SK et al. Diabetic retinopathy: seeing beyond glucose-
induced microvascular disease. Diabetes 2006; 55(9): 2401-2411. 
9. Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein 
Occlusion Study Group. American journal of ophthalmology 1984; 98(3): 271-282. 
10. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein 
occlusion: an evidence-based systematic review. Ophthalmology 2007; 114(3): 507-519, 524. 
11. Giulian D, Li J, Bartel S, Broker J, Li X, Kirkpatrick JB. Cell surface morphology identifies 
microglia as a distinct class of mononuclear phagocyte. J Neurosci 1995; 15(11): 7712-7726. 
12. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of 
microglia in the normal adult mouse brain. Neuroscience 1990; 39(1): 151-170. 
13. Flaris NA, Densmore TL, Molleston MC, Hickey WF. Characterization of microglia and 
macrophages in the central nervous system of rats: definition of the differential expression of 
molecules using standard and novel monoclonal antibodies in normal CNS and in four models 
of parenchymal reaction. Glia 1993; 7(1): 34-40. 
14. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: 
mechanisms and strategies for therapeutic intervention. The Journal of pharmacology and 
experimental therapeutics 2003; 304(1): 1-7. 
15. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in 
neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993; 7(1): 
75-83. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 46 
16. McMillian MK, Thai L, Hong JS, O'Callaghan JP, Pennypacker KR. Brain injury in a dish: a 
model for reactive gliosis. Trends Neurosci 1994; 17(4): 138-142. 
17. Zeiss CJ, Johnson EA. Proliferation of microglia, but not photoreceptors, in the outer nuclear 
layer of the rd-1 mouse. Investigative ophthalmology & visual science 2004; 45(3): 971-976. 
18. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset 
retinal degeneration, and age-related macular degeneration. Exp Eye Res 2003; 76(4): 463-
471. 
19. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more 
than meets the eye. Surv Ophthalmol 2002; 47 Suppl 2: S253-262. 
20. Zeng HY, Green WR, Tso MO. Microglial activation in human diabetic retinopathy. Archives 
of ophthalmology 2008; 126(2): 227-232. 
21. Shin JM, Quan FS, Lee JH, Chun MH, Oh SJ. Neural Cell Attitudes in Ischemic Retinas 
Evoked by Ischemia/Reperfusion and by Venous Cauterization. Invest Ophthalmol Vis Sci; 
51(5): 2243-A423. 
22. Lin CM, Wolpert EB, Shanmugam S, Antonetti DA, Gardner TW, Abcouwer SF. Different 
Effects of Minocycline and Doxycycline on Retinal Vascular Permeability and 
Neurodegeneration in Ischemia-Reperfusion. Invest Ophthalmol Vis Sci; 51(5): 3648-A298. 
23. Lee JE, Liang KJ, Fariss RN, Wong WT. Ex vivo dynamic imaging of retinal microglia using 
time-lapse confocal microscopy. Investigative ophthalmology & visual science 2008; 49(9): 
4169-4176. 
24. Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic 
disease. Clin Neuropharmacol 2004; 27(6): 293-298. 
25. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline 
derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation 
of microglia. J Neurosci 2001; 21(8): 2580-2588. 
26. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix 
metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. 
Curr Med Chem 2001; 8(3): 305-316. 
27. Lampl Y, Boaz M, Gilad R et al. Minocycline treatment in acute stroke: an open-label, 
evaluator-blinded study. Neurology 2007; 69(14): 1404-1410. 
28. Pi R, Li W, Lee NT et al. Minocycline prevents glutamate-induced apoptosis of cerebellar 
granule neurons by differential regulation of p38 and Akt pathways. Journal of neurochemistry 
2004; 91(5): 1219-1230. 
29. Shimazawa M, Yamashima T, Agarwal N, Hara H. Neuroprotective effects of minocycline 
against in vitro and in vivo retinal ganglion cell damage. Brain research 2005; 1053(1-2): 185-
194. 
30. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta 
deposition, and behavior in APP-tg mice. Glia 2006; 53(7): 776-782. 
31. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant 
properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-
scavenging activity. Journal of neurochemistry 2005; 94(3): 819-827. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 47 
32. Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, 
microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. 
Diabetes 2005; 54(5): 1559-1565. 
33. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline 
derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia 
with a wide therapeutic window. Proceedings of the National Academy of Sciences of the 
United States of America 1999; 96(23): 13496-13500. 
34. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit 
microglial activation and are neuroprotective in global brain ischemia. Proceedings of the 
National Academy of Sciences of the United States of America 1998; 95(26): 15769-15774. 
35. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain 
injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. 
Neurosurgery 2001; 48(6): 1393-1399; discussion 1399-1401. 
36. Festoff BW, Ameenuddin S, Arnold PM, Wong A, Santacruz KS, Citron BA. Minocycline 
neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal 
cord injury. Journal of neurochemistry 2006; 97(5): 1314-1326. 
37. Wells JE, Rice TK, Nuttall RK et al. An adverse role for matrix metalloproteinase 12 after 
spinal cord injury in mice. J Neurosci 2003; 23(31): 10107-10115. 
38. Bosco A, Inman DM, Steele MR et al. Reduced retina microglial activation and improved optic 
nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. 
Investigative ophthalmology & visual science 2008; 49(4): 1437-1446. 
39. Yang LP, Zhu XA, Tso MO. A possible mechanism of microglia-photoreceptor crosstalk. 
Molecular vision 2007; 13: 2048-2057. 
40. Leung DW, Lindlief LA, Laabich A et al. Minocycline protects photoreceptors from light and 
oxidative stress in primary bovine retinal cell culture. Investigative ophthalmology & visual 
science 2007; 48(1): 412-421. 
41. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 
2005; 27(9): 1329-1342. 
42. Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research 
Network. A proposed method of logarithmic transformation of optical coherence tomography 
data for use in clinical research. Ophthalmology 2010 Aug; 117(8):1512-6. 
43. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou A, Vergados I. Safety of repeat 
intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 
injections. Retina 2009; 29(3): 313-318. 
44. Yamaike N, Tsujikawa A, Sakamoto A, et al. Retinal sensitivity after intravitreal injection of 
bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Retina 
2009; 29: 757-767. 
45. Winterhalter S, Lux A, Maier AK, et al. Microperimetry as a routine diagnostic test in the 
follow-up of retinal vein occlusion? Graefes Arch Clin Exp Ophthalmol 2011; 
doi:10.1007/s00417-011-1784-8 
46. Senturk F, Ozdemir H, Karacorlu M, Karacorlu SA, Uysal O. Microperimetric changes after 
intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein 
occlusion. Retina 2010; 30: 1254-1261. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 48 
47. Schneider U, Inhoffen W, Grisanti S, Bartz-Schmidt KU. Characteristics of visual field defects 
by scanning laser ophthalmoscope microperimetry after radial optic neurotomy for central 
retinal vein occlusion. Retina 2005; 25: 704-712. 
48. Schmidt B, Krummenauer F, Losche CC. [Evaluation of Possible Prognostic Factors for the 
Course of Visual Acuity after Intravitreal Ttriamconolone Acetonide.]. Klin Monbl 
Augenheilkd 2011; 229(1), 56-61. doi: 10.1055/s-0031-1281586. 
49. Ogino K, Tsujikawa A, Murakami T, et al. Evaluation of macular function using focal macular 
electroretinography in eyes with macular edema associated with branch retinal vein occlusion. 
Investigative Ophthalmology & Visual Science 2011; 52(11): 8047-8055.  
50. Noma H, Funatsu H, Mimura T, Shimada K. Visual function and serous retinal detachment in 
patients with branch retinal vein occlusion and macular edema: a case series. BMC Ophthalmol 
2011; 11, 29. 
51. Noma H, Funatsu H, Mimura T, Harino S, Shimada K. Functional-morphologic correlates in 
patients with branch retinal vein occlusion and macular edema. Retina 2011; 31(10), 2102-
2108. 
52. Kriechbaum K, Prager F, Geitzenauer W, et al. Association of retinal sensitivity and 
morphology during antiangiogenic treatment of retinal vein occlusion over one year. 
Ophthalmology 2009; 116(12): 2415-2421. 
53. Fujii GY, de Juan E, Jr., Humayun MS. Improvements after sheathotomy for branch retinal 
vein occlusion documented by optical coherence tomography and scanning laser 
ophthalmoscope. Ophthalmic Surg Lasers Imaging 2003; 34(1): 49-52. 
54. Chalam KV, Shah VA. Resolution of macular scotoma after radial optic neurotomy in central 
retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2006; 37(1): 72-75. 
55. Barbazetto IA, Schmidt-Erfurth UM. [Quantification of functional retinal damage in branch 
retinal vein thromboses]. Ophthalmologe 1999; 96(3): 159-165. 
 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 49 
APPENDIX 1: DETERMINING CHILDBEARING POTENTIAL 
A female participant who is considered non-childbearing due to a medical condition  
(i.e., participant has previously undergone a hysterectomy) does not need a pregnancy test, 
Follicle-stimulating Hormone (FSH) test or contraception. 
If a female participant is considered non-childbearing due to menopause, it must be in accordance 
with the CNS IRB/NIH Ob-Gyn guidance on the definition of menopause. This guidance defines 
menopause as: 
 Women over age 55 who have not had a period for one year will be considered menopausal 
and do not need a pregnancy test, FSH test or contraception. 
 Women between 50 and 55, who have not had a period for one year, should have an FSH 
test. If their FSH level is ≥ 20 mIU/mL, they will be considered menopausal and do not 
need pregnancy testing or contraception. If their FSH level is < 20 mIU/mL, they will need 
pregnancy testing and contraception as required by the protocol. 
 Women between 45 and 50 who have not had a period for one year will need both an FSH 
test and a pregnancy test. If they are not pregnant and their FSH level is ≥ 20 mIU/mL, 
they will be considered menopausal and will not require contraception or additional 
pregnancy testing. If their FSH test is < 20 mIU/mL, they will need pregnancy testing and 
contraception as required by the protocol. 
 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 50 
APPENDIX 2: STUDY FLOWSHEET 
Study Visit Number* (Month) 
0 
1 
2 
3-11 
12 
13-23 
24 
SFTY13 
Visit Number
00
01
02
03-11
12
13-23
24
SFTY
Target Day from Baseline Visit
000
030
060
090-334
365
395-699
730
735
Treatment14 
Dispense Investigational Product1 
(taken twice daily2) 
X 
X 
X 
X3 
X3 
X3 
 
 
Drug Accountability Review
X
X
X
X
X
X
Bevacizumab Injection
X
X
X
X3
X3
X3
General Assessments14 
 
 
 
 
 
 
 
 
Medical/Ophthalmic History
X
Vital Signs
X
Physical Examination
X6
Thyroid Palpation4
X
X
X
X
X
X
X
Review of Systems
X
X
X
X
X
X
X
Allergies Assessment
X
Concomitant Medications 
Assessment
X 
X 
X 
X 
X 
X 
X 
X 
Adverse Event Assessment
X
X
X
X
X
X
X
Ophthalmic Assessments14
BCVA (ETDRS)
X
X
X
X
X
X
X
X
Manifest Refraction5
X
X
X
Slit Lamp Examination 
X 
X
X
X
X
X
X
X
Dilated Fundus Examination 
X
X
X
X
X
X
X
Intraocular Pressure (IOP)
X
X
X
X
X
X
X
X
Color Fundus Photography (CFP) 
X6
X
X
Spectral Domain Optical 
Coherence Tomography (OCT) 
X6 
X 
X 
X 
X 
X 
X 
X 
Microperimetry
X6
X7
X
X7
X
Fluorescein Angiogram (FA) 
X6
X
X
Laboratory Assessments8, 14 
Acute Care Panel
X9
X
X10
X10
X
X
Hepatic Panel
X9
X
X10
X10
X
X
Complete Blood Count (CBC)
X9
X
Thyroid Function Test11 
X9
X
X10
X10
X
Pregnancy Test (urine)12 
X
X
X
X
X
X
X
 
* These visit numbers correspond with the protocol visit numbers. All follow-up visits will be conducted within a window 
of 7 days of the target day, with the exception of the safety follow-up visit at the BRC sites, which can only occur at 
least five days following IP cessation. 
1 At the time the study medication is dispensed, participants will be provided a pill diary and an information sheet outlining 
instructions on taking study medication and concomitant medications.  
2 Participants will take an oral pill two times a day, once in the morning and once in the evening, approximately  
12 hours apart. The exception to this will occur on the day of the baseline visit, in which participants will take only the 
evening pill.  
3 The decision to continue dispensing IP or injecting bevacizumab is determined by the scenarios described in Section 
4.5.2. 
4  Abnormal findings during a thyroid palpation will be followed by a referral to an endocrinologist.  
5 BCVA with manifest refraction must also be performed when scheduled and when there is a change in VA of  
>10 ETDRS letters (> 0.20 logMAR) as compared with relevant baseline. 
6 These procedures may be completed under another NEI protocol if performed within 1-7 days prior to the baseline visit. 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 51 
7 Microperimetry will be performed at baseline and at Months 3, 6, 12, 18 and 24. 
8 All abnormal values or positive tests will be reported to the participant’s primary care physician, with the participant’s 
permission. 
9 These procedures may be completed under another NEI protocol if performed within 42 days prior to the baseline visit. 
10  The acute care and hepatic panels and thyroid function testing are performed at baseline, Month 2 and every four months 
thereafter (Months 6, 10, 14, 18 and 22), as well as the final visit at Month 24. 
11  Participants with abnormal thyroid function test results will be referred to an endocrinologist. 
12 For women of childbearing potential only and they must have a negative test within 24 hours prior to initiation of IP. 
For the BRC sites, for women of childbearing potential only and they must have a negative serum pregnancy test within 
24 hours prior to initiation of IP. After initiation of contraception, urine pregnancy tests will be conducted; however, a 
serum test will be performed anytime a urine test result creates doubt. See Appendix 1 for guidance on determining 
whether a female is considered to be of childbearing potential. Some women may require a follicle-stimulating hormone 
(FSH) test to determine childbearing potential.  
13 Applicable to the BRC sites only: This visit must be conducted at least five days after the last study drug administration. 
Additional assessments may be performed if deemed necessary by the investigator. 
14 Applicable to the BRC sites only: In the event that the baseline testing was not completed within one day, subsequent 
clinic visits may be scheduled within 14 days of the first visit to complete the scheduled evaluations and treatments. If 
the Month 12 or Month 24 visit was not completed within one day, subsequent visits may be scheduled within 7 days of 
the first visit. If the baseline visit, Month 12 visit or Month 24 visit are conducted over more than one day, BCVA, OCT 
and microperimetry testing must be completed on the day of the injection. 
 
 
 


MiCRVO 
September 19, 2018 
Version 19.0 
CONFIDENTIAL 
Page 52 
APPENDIX 3: LIST OF DEFINITIONS 
 
Improvement: Visual acuity in the study eye of > 84-88 letters (20/20) OR OCT central 
subfield thickness < 300 microns. 
 
Worsening: A decrease in visual acuity of ≥15 or more letters in the study eye compared 
to baseline, AND an increase in OCT central subfield thickness ≥ 1-step log unit compared 
to baseline for at least two consecutive visits. 
 
New Steady State: Improvement and worsening criteria not met and central subfield 
thickness remains ≥ 300 microns on OCT but thickness is stable and has not changed  
> 25 microns over the last three consecutive injections. 
 
No improvement: Improvement and worsening criteria are not met and visual acuity failed 
to increase by ≥ 10 letters in the study eye compared to baseline AND OCT central subfield 
thickness failed to decrease by ≥ 1-step log unit compared to baseline. 

SAP_001.pdf: 
Statistical Analysis Plan 
For 
A Pilot Study for the Evaluation of Minocycline as a  
Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions 
 
 
 
Version 1.0 
April 14, 2020 
 
Prepared by Megan Wall 
 
 
 
Original Author Signature: 
 
__________________________________________ 
 
 
 
 
 
Megan Wall, MS 
 
Reviewer Signature:  
 
__________________________________________ 
 
 
 
 
 
Michael Rothe, MS 
 
Principal Investigator Signature: 
__________________________________________ 
 
 
 
 
 
Catherine Cukras, MD, PhD 


MiCRVO SAP 
April 14, 2020 
 
TABLE OF CONTENTS 
Version 1.0 
Confidential 
Page i 
1.0 
INTRODUCTION ............................................................................................................................. 4 
1.1 
Central Retinal Vein Occlusions (CRVO) ...................................................................................... 4 
2.0 
DATA SOURCE ............................................................................................................................... 5 
3.0 
GENERAL REVIEW OF STUDY DESIGN ......................................................................................... 5 
3.1 
Randomization, Masking and Unmasking ...................................................................................... 5 
3.2 
Study Design .................................................................................................................................. 6 
3.2.1 
Treatment Prior to Month 3 ..................................................................................................... 7 
3.2.2 
Treatment Beginning at Month 3 ............................................................................................ 7 
3.2.3 
Criteria for Stopping the Study ............................................................................................... 9 
3.3 
Study Objective .............................................................................................................................. 9 
3.4 
Study Population ............................................................................................................................ 9 
3.4.1 
Inclusion Criteria ..................................................................................................................... 9 
3.4.2 
Exclusion Criteria .................................................................................................................. 11 
3.5 
Study Eye Eligibility Criteria ....................................................................................................... 12 
3.5.1 
Study Eye Inclusion Criteria ................................................................................................. 12 
3.5.2 
Study Eye Exclusion Criteria ................................................................................................ 13 
3.5.3 
Choice of Study Eye in Cases of Bilateral Eligibility ........................................................... 14 
3.6 
Outcome Measures ....................................................................................................................... 14 
3.6.1 
Primary Study Outcome ........................................................................................................ 14 
3.6.2 
Secondary Study Outcomes .................................................................................................. 14 
3.6.3 
Safety Outcomes ................................................................................................................... 15 
4.0 
STATISTICAL CONSIDERATIONS ................................................................................................ 15 
4.1 
Sample Size .................................................................................................................................. 15 
4.2 
Analysis Population ...................................................................................................................... 15 
4.3 
Descriptive Statistics .................................................................................................................... 15 
4.4 
Handling of Missing Values ......................................................................................................... 16 
4.5 
Handling Duplicate Assessments ................................................................................................. 16 
4.6 
Software for Analyses .................................................................................................................. 16 
5.0 
PARTICIPANT DISPOSITION ........................................................................................................ 17 
6.0 
PARTICIPANT CHARACTERISTICS .............................................................................................. 17 
6.1 
Participant Demographics ............................................................................................................ 17 
6.2 
Medical and Ophthalmic History ................................................................................................. 18 
7.0 
PARTICIPANT COMPLIANCE ....................................................................................................... 18 
7.1 
Protocol Deviations and Unanticipated Problems ........................................................................ 18 
7.1.1 
IP Compliance Deviations ..................................................................................................... 18 
7.2 
Study Procedure Deviations ......................................................................................................... 19 
7.3 
Visit Schedule Deviations ............................................................................................................ 19 
8.0 
TREATMENT ................................................................................................................................ 20 
9.0 
STOPPING THE STUDY ................................................................................................................. 20 
10.0 
PRIMARY OUTCOMES ANALYSIS ................................................................................................ 20 
11.0 
SECONDARY OUTCOMES ANALYSIS ............................................................................................ 20 
11.1 Number of Bevacizumab Injections ............................................................................................. 21 
11.2 Macular Sensitivity ....................................................................................................................... 21 
11.3 Best-Corrected Visual Acuity (BCVA) ........................................................................................ 21 
11.4 Optical Coherence Tomography (OCT) ....................................................................................... 21 
11.5 Improvement of ≥ 1 logOCT Scale Step ...................................................................................... 22 


MiCRVO SAP 
April 14, 2020 
 
TABLE OF CONTENTS (CONTINUED) 
Version 1.0 
Confidential 
Page ii 
11.6 Changes in Fluid Leakage ............................................................................................................ 22 
12.0 
SAFETY ANALYSIS ....................................................................................................................... 23 
12.1 Adverse Events (AEs) .................................................................................................................. 23 
12.2 Withdrawal from IP Due to Vision Loss and Adverse Events and Participants with Worsening 
Disease .................................................................................................................................................... 23 
12.3 Best-Corrected Visual Acuity ....................................................................................................... 23 
12.4 Optical Coherence Tomography (OCT) ....................................................................................... 24 
12.5 Intraocular Pressure (IOP) ............................................................................................................ 24 
12.6 Thyroid Palpation Assessment and Review of Systems ............................................................... 24 
12.7 Laboratory Assessments ............................................................................................................... 24 
12.8 Other Safety Outcomes ................................................................................................................. 25 
13.0 
QUALITY ASSURANCE PLANS ..................................................................................................... 25 
14.0 
REFERENCES ............................................................................................................................... 25 
15.0 
MOCK SHELLS ............................................................................................................................. 27 
 
LIST OF TABLES 
 
Table 1: Participant Disposition .................................................................................................................. 27 
Table 2: Demographic Information by Treatment Arm .............................................................................. 28 
Table 3: Medical and Ocular History .......................................................................................................... 29 
Table 4: Protocol Deviations and Unanticipated Problems ........................................................................ 30 
Table 5: Missed Study Procedures .............................................................................................................. 30 
Table 6: Missed and Out of Window Study Visits ..................................................................................... 31 
Table 7: Analysis of Primary Outcome of Change in BCVA of the Study Eye from Baseline at Month 12
 ..................................................................................................................................................... 31 
Table 8: Analysis of Secondary Outcome of Number of Bevacizumab Injections by Participant from 
Baseline to Month 12 and from Baseline to Month 24 ............................................................... 32 
Table 9: Analysis of Secondary Outcome of Summary of Bevacizumab Injections by Treatment Arm 
from Baseline to Month 12 and from Baseline to Month 24 ....................................................... 32 
Table 10: Analysis of Secondary Outcome of Change in Macular Sensitivity as Measured by 
Microperimetry from Baseline at Months 3, 6, 12, 18 and 24 .................................................... 33 
Table 11: Analysis of Secondary Outcome of Change in BCVA of the Study Eye from Baseline at Month 
24 ................................................................................................................................................. 33 
Table 12: Analysis of Secondary Outcome of Change in Central Retinal Thickness of the Study Eye from 
Baseline at Months 6, 12, 18 and 24 ........................................................................................... 33 
Table 13: Analysis of Secondary Outcome of Number of Participants Improving ≥ 1 logOCT Scale Step 
in the Study Eye at 12 and 24 Months Compared to Baseline .................................................... 33 
Table 14: Analysis of Secondary Outcome of Change in Fluid Leakage in the Macula in the Study Eye at 
12 and 24 Months Compared to Baseline ................................................................................... 33 
Table 15: Summary of Adverse Events ...................................................................................................... 34 
Table 16: Summary of Adverse Events by System Organ Class (SOC) and Preferred Term (PT) ............ 35 
Table 17: Summary of Visual Acuity Over Time ....................................................................................... 36 
Table 18: Summary of Central Retinal Thickness Over Time .................................................................... 37 
Table 19: Summary of IOP Over Time ....................................................................................................... 37 
Table 20: Results of Thyroid Palpation Assessment and Review of Systems Over Time .......................... 37 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page iii 
Table 21: Summary of Laboratory Assessments Over Time ...................................................................... 38 
 
LIST OF FIGURES 
 
Figure 1: Consort Diagram ......................................................................................................................... 39 
Figure 2: Mean Best-Corrected Visual Acuity Over Time by Treatment Arm .......................................... 40 
Figure 3: Best-Corrected Visual Acuity Over Time by Participant ............................................................ 41 
Figure 4: Mean Central Retinal Thickness Over Time by Treatment Arm ................................................ 41 
Figure 5: Central Retinal Thickness Over Time by Participant .................................................................. 41 
 
 
LIST OF LISTINGS 
Listing 1: Demographic Information by Participant ................................................................................... 42 
Listing 2: IP Compliance ............................................................................................................................ 42 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 4 
1.0 
INTRODUCTION 
This statistical analysis plan (SAP) provides the proposed analyses for the MiCRVO protocol titled  
“A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of 
Central Retinal Vein Occlusions”. This document contains fifteen sections: (1) background of the 
study, (2) data sources for analyses, (3) an overview of the study design, (4) statistical 
considerations, (5) participant disposition, (6) participant characteristics, (7) participant 
compliance, (8) treatment, (9) criteria for stopping the study, (10) statistical analysis for the 
primary outcome, (11) statistical analyses for the secondary outcomes, (12) review of safety 
analyses, (13) quality assurance plans, (14) references, and (15) proposed data tables, figures and 
listings. This document is based on version 22.0 of the protocol dated December 10, 2019.  
1.1 
Central Retinal Vein Occlusions (CRVO) 
Retinal vein occlusions (RVOs) are a significant source of vision loss, affecting mostly healthy 
people over 55 years of age. The common source of vision loss is the macular edema 
accompanying the retinal injury. The two main types of RVOs are branch retinal vein occlusions 
(BRVO) and central retinal vein occlusions (CRVO). Prevalence of CRVO is approximately 0.1% 
(1, 2). The fundamental cause of macular edema associated with RVOs is not completely 
understood, but it is increasingly clear that its pathophysiology extends beyond microvascular 
disease to involve immune mediators in the retina, such as microglia. Retinal microglia, derived 
from the monocytic lineage, are resident cells in the healthy retina that may be construed as 
representatives of the immune system in the immune-privileged environment of the retina.  
There is accumulating evidence that retinal microglia are associated with inflammation in the 
retina in conditions such as diabetic retinopathy and the RVOs. Therefore, microglia represent a 
promising cellular target for forms of therapy that limit the deleterious inflammatory changes 
found in vein occlusions. Minocycline, a second-generation tetracycline with anti-inflammatory 
properties and high lipophilicity, appears to inhibit the activation of microglia as has been observed 
in animal studies and culture (3-6). Minocycline is used widely clinically and has been shown to 
be well tolerated when used at the FDA-approved doses proposed in this study. The objective of 
this study is to investigate the safety and potential efficacy of minocycline, a microglia inhibitor, 
in the treatment of CRVO. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 5 
2.0 
DATA SOURCE 
Data received from the National Eye Institute (NEI) will be collected via their electronic data 
capture system (EMR), and uploaded on a daily basis to the Coordinating Center’s database, 
Advantage EDC. Microperimetry data will be provided directly to the Coordinating Center from 
the NEI. Data received from the Bristol Eye Hospital (BEH) will be collected directly through 
Advantage EDC.  
3.0 
GENERAL REVIEW OF STUDY DESIGN 
3.1 
Randomization, Masking and Unmasking 
After the participant is determined eligible and has completed the informed consent process, the 
group will be assigned based on a predetermined randomization schedule developed by the 
Coordinating Center. Randomization will be stratified by site. 
Randomization must occur on the same day as the initial administration of investigational product 
(IP) while the participant and the ophthalmologist are present and will not be permitted any time 
before. Participant eligibility must be confirmed before a participant is randomized. Participants 
will be randomized to one of two groups with equal probability for equal numbers of participants 
in each group: minocycline or placebo. Participants must continue to receive the same treatment 
regimen to which they were assigned for the duration of the study. 
All clinic staff and participants will be masked to group assignments. Only designated pharmacy 
personnel, select individuals at the Emmes Company, LLC, and the NEI Data and Safety 
Monitoring Committee (DSMC) will have access to the group assignments.  
Participants will be unmasked if deemed clinically necessary by the examining physician and if 
the study Principal Investigator (PI) and DSMC Chair are in agreement. In the case of a medical 
emergency, the examining or treating physician will have the final decision and unilateral right for 
unmasking. A request for unmasking, after approval by the PI and the DSMC Chair, will be made 
to Coordinating Center personnel, who will inform the PI and the DSMC Chair of the group 
assignment. Attempts should be made to maintain the masking of the investigators prior to the 
study-wide unmasking. Unmasking will be recorded on an adverse event (AE) form. All instances 
of unmasking must be reported to the ICRRC, the NIH IRB, and the DSMC. At the conclusion of 
the study, all investigators will be unmasked.  


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 6 
3.2 
Study Design 
For the NEI Site: The study duration will be 24 months. During this period, participants will be 
instructed to take the IP (either placebo or minocycline 100 mg capsule) twice daily. The primary 
outcome will be assessed at Month 12, and secondary outcomes will be assessed at 3, 6, 12, 18 
and 24 months. Visits will occur at baseline, and then monthly or as clinically indicated. The study 
will require a minimum of 25 visits (baseline and Months 1-24). All appointments must be 
conducted within a window of ± seven days from the target day. The tests scheduled at each visit 
will be completed in one day. At each visit, the participant will undergo a review of systems and 
an assessment of safety variables. A complete ophthalmologic examination will be performed at 
each visit to measure outcome variables.  
During each clinic visit, participants will have their visual acuity measured and will undergo OCT 
testing to measure retinal thickness.  
For the BRC Sites: The study duration will be approximately 24 months. During this period, 
participants will be instructed to take the IP (either placebo or minocycline 100 mg capsule) twice 
daily. The primary outcome will be assessed at Month 12, and secondary outcomes will be assessed 
at 3, 6, 12, 18 and 24 months. Visits will occur at baseline, and then monthly or as clinically indicated. 
The study will require a minimum of 26 appointments (baseline and Months 1-24 and safety 
follow-up). All appointments must be conducted within a window of ± seven days from the target 
day, except for the safety follow-up visit which must occur at least five days after the cessation of 
IP. The tests scheduled at each visit are expected to be completed in one day, with the exception 
of the baseline visit, Month 12 visit and Month 24 visit. If the baseline examinations cannot be 
performed in one clinic visit over one day, it is acceptable that the baseline examinations be 
completed at subsequent clinic visits, if scheduled within fourteen days of the first visit. If the 
Month 12 and Month 24 examinations cannot be performed in one clinic visit over one day, it is 
acceptable that the examinations be completed at subsequent clinic visits, if scheduled within 
seven days of the first visit. At each visit, the participant will undergo a review of systems and an 
assessment of safety variables. A complete ophthalmologic examination will be performed at each 
visit (except for the safety follow-up visit) to measure outcome variables. If the baseline visit, 
Month 12 visit, or Month 24 visit are conducted over more than one day, BCVA, OCT and 
microperimetry testing must be conducted on the day of the injection. If a participant or site is 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 7 
unable to complete microperimetry testing, the testing may be waived and the investigator will 
specify the reason the test could not be completed. 
During each study visit, with the exception of the Month 24 visit and safety follow-up visit at the 
BRC sites, IP will be dispensed to the participant unless the treatment is deemed to be “worsening” 
or to offer “no improvement” and the participant and the investigator decide to stop IP. An 
information sheet outlining instructions on taking the study medication and concomitant 
mediations will be distributed to participants and discussed in detail by study personnel. They will 
be asked to inform any physician who is prescribing new medications that they are currently taking 
minocycline. In addition, the participants will be asked to inform a study team member if a new 
medication is prescribed to them.  
Participant compliance with IP will be prompted through ongoing encouragements and reminders 
during study visits and scheduled and unscheduled telephone contacts. Compliance will be 
assessed by pill counts conducted during study visits and the participant’s pill diary.  
Once identified, occurrences in which the computed compliance rate between study visits falls 
below 50% will be reported as a protocol deviation to the NIH IRB within two weeks using iRIS.  
3.2.1 Treatment Prior to Month 3 
At baseline, the participant will receive an injection of 1.25 mg bevacizumab, an anti-VEGF agent, 
and also start the randomized IP. At Months 1 and 2, the participant will again receive bevacizumab 
injections in the study eye and continue the randomized IP.  
3.2.2 Treatment Beginning at Month 3 
Visual acuity and macular edema will be evaluated at study visits to determine further treatment. 
Starting at Month 3 and at every visit thereafter, the following scenarios will be considered.  
The participant will be re-injected with bevacizumab unless the participant meets the 
“improvement,” “worsening,” “new steady state” or “no improvement” criteria defined below. 
Scenario 1: If the participant meets the “improvement” criteria, the participant will continue to 
take the IP, but the bevacizumab injection will be withheld at that visit. 
Scenario 2: If the participant meets the “worsening” criteria, the participant will be offered any 
therapy available at the discretion of the treating investigator, including: 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 8 
a. Anti-VEGF Treatment. 
b. Intravitreal or Periocular Steroid Injections. 
Scenario 3: If the participant does not meet the “improvement” or “worsening” criteria, but meets 
the “new steady state” criteria, the treating investigator physician will have the discretion to hold 
bevacizumab injections until the OCT changes (worsens) by > 25 microns from this “new steady 
state” level. 
At the Month 12 visit and at every visit thereafter, Scenarios 1, 2 and 3 will be considered as well 
as the following scenario, which allows for a study physician to determine whether there has been 
“no improvement” in the participant’s condition: 
Scenario 4: If the participant meets the “no improvement” criteria or if the investigator’s clinical 
impression is that there has been no improvement in the study eye, the participant will be offered 
therapy at the discretion of the treating investigator. The decision to re-inject the participant with 
bevacizumab (the anti-VEGF agent) will be made by the treating investigator after consulting with 
the participant. The decision to continue the IP will also be made by the treating investigator after 
consulting with the participant. 
The “improvement,” “worsening,” “new steady state,” and “no improvement” criteria are defined 
as follows: 
• Improvement: Visual acuity in the study eye of ≥ 84-88 letters (20/20) OR OCT central 
subfield thickness < 300 microns.  
• Worsening: A decrease in visual acuity of ≥ 15 or more letters in the study eye compared 
to baseline, AND an increase in OCT subfield thickness ≥ 1-step log unit compared to 
baseline for at least two consecutive visits.  
• New steady state: Improvement and worsening criteria not met and central subfield 
thickness remains ≥ 300 microns on OCT, but thickness is stable and has not changed > 25 
microns over the last three consecutive injections.  
• No improvement: Improvement and worsening criteria are not met and visual acuity failed 
to increase by ≥ 10 letters in the study eye compared to baseline AND OCT central subfield 
thickness failed to decrease by ≥ 1-step log unit compared to baseline.  


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 9 
3.2.3 Criteria for Stopping the Study 
The DSMC may recommend temporarily suspending or closing enrollment, or stopping the study 
at any time due to safety concerns, demonstration of efficacy or lack of efficacy, or slow 
recruitment. Criteria for stopping the study include the following: 
• A sufficiently large number of dropouts occurs as to make the trial likely to be 
uninformative; 
• A participant experiences a drop in BCVA in the study eye of  30 letters from baseline 
attributed to the IP; 
• A participant experiences a serious adverse event (SAE), drug reaction or complication, 
whether attributed to the IP or not, which has an impact on visual function or any other 
body system or precludes continuation of the IP. This would include the development of 
hypersensitization, allergic responses or other potentially serious drug reactions to 
medications required by the protocol. 
Following premature IP discontinuation, not due to an AE, participants will continue to be 
followed as per the protocol. 
3.3 
Study Objective 
The objective of this study is to investigate the safety and potential efficacy of minocycline, a 
microglia inhibitor, in the treatment of CRVO. 
3.4 
Study Population 
A minimum of 10 and a maximum of 20 participants who meet the eligibility criteria may be 
enrolled. 
3.4.1 Inclusion Criteria 
To be eligible, the following inclusion criteria must be met, where applicable. 
1. Participant is 18 years of age or older. 
2. Participant must understand and sign the protocol’s informed consent document. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 10 
3. Female participants of childbearing potential must not be pregnant or breast-feeding and 
must be willing to undergo serum (BRC sites only) and urine pregnancy tests throughout 
the study. 
4. For the NEI Site: Female participants of childbearing potential and male participants able 
to father children must have (or have a partner who has) had a hysterectomy or vasectomy, 
be completely abstinent from intercourse or must agree to practice two acceptable methods 
of contraception throughout the course of the study and for one week after study medication 
discontinuation (based on the half life of minocycline which is 11-22 hours).  
Acceptable methods of contraception include: 
• hormonal contraception (i.e., birth control pills*, injected hormones, dermal patch 
or vaginal ring), 
• intrauterine device, 
• barrier methods (diaphragm, condom) with spermicide, or 
• surgical sterilization (hysterectomy or tubal ligation). 
*Oral birth control pills must be used with caution as minocycline decreases the 
effectiveness of some oral contraceptives. Participants already taking oral contraceptives 
may continue to use them, but must agree to use at least one other method of birth control 
while on study. 
5. For the BRC Sites: Female participants of childbearing potential and male participants able 
to father children must have (or have a partner who has) had a hysterectomy or vasectomy, 
or be completely abstinent from intercourse. Male participants or male partners (of female 
participants) who have not had a vasectomy or are not abstinent are required to use a 
condom with spermicide throughout the course of the study and for one week after study 
medication discontinuation (based on the half life of minocycline which is 11-22 hours). 
Female participants of childbearing potential or female partners (of male participants) of 
childbearing potential must practice one of the below acceptable methods of contraception 
throughout the course of the study and for one week after study medication discontinuation: 
• hormonal contraception (i.e., birth control pills*, injected hormones, dermal patch 
or vaginal ring), 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 11 
• intrauterine device, 
• barrier methods (diaphragm, condom) with spermicide, or 
• surgical sterilization (hysterectomy or tubal ligation). 
Abstinence is only acceptable when it is the participant’s preferred and usual lifestyle 
choice. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception. 
*Oral birth control pills must be used with caution as minocycline decreases the 
effectiveness of some oral contraceptives. Participants already taking oral contraceptives 
may continue to use them, but must agree to use at least one other method of birth control 
while on study. 
It should be noted that two forms of contraception (as specified above) will be used by 
sexually active participants for the duration of the study and for one week after study 
medication discontinuation. 
6. Participants must agree to notify the study investigator or coordinator if any of their doctors 
initiate a new medication during the course of the study. 
7. Participant must have normal renal function and liver function or have mild abnormalities 
not above grade 1 as defined by the Common Terminology Criteria for Adverse Events 
v4.0 (CTCAE). 
8. Participant has at least one eye that meets the study eye criteria listed in Section 3.5. 
3.4.2 Exclusion Criteria 
A participant is not eligible if any of the following exclusion criteria are present. 
1. Participant is in another investigational study and actively receiving IP for CRVOs. 
2. Participant is unable to comply with study procedures or follow-up visits. 
3. Participant has a known hypersensitivity to sodium fluorescein dye. 
4. Participant has a condition that, in the opinion of the investigator, would preclude 
participation in the study (e.g., unstable medical status including blood pressure and 
glycemic control). 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 12 
5. Participant has a history of chronic renal failure requiring dialysis or kidney transplant. 
6. Participant has a history of chronic hepatitis or liver failure. 
7. Participant has an allergy or hypersensitivity to minocycline or any drug in the 
tetracycline family. 
8. Participant is currently taking a tetracycline medication. 
9. Participant is taking any medication that could adversely interact with minocycline 
such as methoxyflurane. 
10. Participant has a blood pressure of > 180/110 (systolic above 180 OR diastolic above 
110). 
• If blood pressure is brought below 180/110 by anti-hypertensive treatment, the 
participant can become eligible. 
11. Participant is currently being treated with systemic anti-VEGF agents or systemic 
steroids. 
12. Participant had a cerebral vascular event (CVA) or myocardial infarction (MI) within 
three months prior to study entry. 
13. Participant has a history of thyroid cancer. 
3.5 
Study Eye Eligibility Criteria 
The participant must have at least one eye meeting all inclusion criteria and none of the exclusion 
criteria listed below. 
3.5.1  Study Eye Inclusion Criteria 
1. The study eye has a best-corrected ETDRS visual acuity score between 78 and 34 
letters (i.e., between 20/32 and 20/200). 
2. The study eye shows definite retinal thickening due to a CRVO based on clinical 
examination involving the center of the macula that is not refractory to further therapy 
as based on the investigator’s clinical judgment. CRVO is defined as an eye that had 
retinal hemorrhage or other biomicroscopic evidence of RVO (e.g., telangiectatic 
capillary bed) and a dilated (or previously dilated) venous system in at least three 
quadrants of the retina drained by the affected vein. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 13 
3. The study eye has retinal thickness in the central subfield on baseline OCT 
measurement > 350 microns, as measured by Zeiss Cirrus spectral domain OCT, or an 
equivalent retinal thickness on a similar OCT machine. 
4. The study eye has media clarity and pupillary dilation sufficient for adequate fundus 
photographs. Furthermore, the participant must be able to cooperate during the 
procedure for accurate fundus photographs. 
3.5.2 Study Eye Exclusion Criteria 
1. The study eye has macular edema considered to be due to a cause other than CRVO. 
2. An eye should not be considered eligible if: 
• The macular edema is considered to be related to cataract extraction, or 
• Clinical examination and/or OCT suggest that vitreoretinal interface disease  
(e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the 
macular edema, or 
• Clinical examination, medical history and/or fluorescein angiography suggest that 
diabetic retinopathy is the primary cause of the edema. 
3. The study eye has a history of a recurrent RVO. 
4. The study eye has a history of RVO present for > 18 months. 
5. A brisk afferent pupillary defect (APD) is present in the study eye. 
6. An ocular condition (other than RVO) is present in the study eye such that, in the 
opinion of the investigator, visual acuity would not improve from resolution of macular 
edema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, laser 
scar at fovea, non-retinal condition). 
7. An ocular condition (other than RVO) is present that, in the opinion of the investigator, 
might affect macular edema or alter visual acuity during the course of the study 
(e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular 
glaucoma, Irvine-Gass Syndrome, etc.). 
8. A substantial cataract that, in the opinion of the investigator, is likely to be decreasing 
visual acuity by three lines or more (i.e., cataract would be reducing acuity to 20/40 or 
worse if eye was otherwise normal) is present in the study eye. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 14 
9. The study eye has had panretinal or sectoral scatter photocoagulation (PRP) within four 
months prior to study entry. 
10. The study eye has had pars plana vitrectomy within six months prior to study entry. 
11. The study eye has undergone major ocular surgery (including cataract extraction, 
scleral buckle, any intraocular surgery, etc.) within three months prior to study entry. 
12. A yttrium aluminum garnet (YAG) capsulotomy has been performed on the study eye 
within two months prior to study entry. 
13. The study eye has had treatment < three months prior to study entry of intravitreal or 
periocular steroid injections. 
14. The study eye has had treatment < 28 days prior to study entry of intravitreal anti-
VEGF agents. 
3.5.3 Choice of Study Eye in Cases of Bilateral Eligibility 
If both eyes of a participant meet the criteria described in Sections 3.5.1 and 3.5.2, the study eye 
will be determined at the investigator’s discretion.  
3.6 
Outcome Measures 
3.6.1 Primary Study Outcome 
The primary outcome is the difference in mean change of BCVA, as measured in ETDRS letters, 
between the minocycline and placebo groups in the study eye at 12 months compared to baseline. 
3.6.2 Secondary Study Outcomes 
Secondary outcomes include the difference between the minocycline and placebo groups in the: 
• Number of bevacizumab injections from baseline to 12 months and from baseline to 24 
months,  
• Changes in mean macular sensitivity as measured by microperimetry at 3, 6, 12, 18 and 24 
months compared to baseline, 
• Mean change in the ETDRS BCVA in the study eye at 24 months compared to baseline, 
• Changes in the retinal thickness in the study eye as measured by OCT at 6, 12, 18 and 24 
months compared to baseline, 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 15 
• Number of participants improving ≥ 1 logOCT scale step at 12 and 24 months compared 
to baseline, 
• Changes in fluid leakage in the macular as demonstrated by fluorescein angiography at 12 
and 24 months compared to baseline. 
3.6.3 Safety Outcomes 
Safety outcomes will be the number and severity of systemic and ocular toxicities and AEs.  
The number of participants withdrawn from the IP due to vision loss or AEs and the number of 
participants deemed to have worsening disease will also contribute to the assessment of safety. 
4.0 
STATISTICAL CONSIDERATIONS 
4.1 
Sample Size 
No formal sample size has been calculated. The accrual ceiling for this study is 20 participants  
(10 per group) with a minimum of 10 participants (five per group). This number was selected to 
obtain at least five participants in each group reaching the final study visit in order to obtain 
preliminary data to potentially support a larger trial if promising results are revealed.  
4.2 
Analysis Population 
The following analysis populations will be considered for this study: 
Enrolled population: Includes all participants enrolled in the study, regardless of compliance, 
follow-up or treatment received.  
Safety population: Includes all participants who were exposed to IP, regardless of adherence to the 
protocol. 
Primary outcome analysis population: Includes those participants who were exposed to IP and 
were followed up for at least 12 months.  
4.3 
Descriptive Statistics 
For continuous parameters, such as visual acuity, central retinal thickness as measured by optical 
coherence tomography, and macular sensitivity as measured by microperimetry, descriptive 
statistics will include the number of observations, mean, standard deviation, median, minimum 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 16 
and maximum. For categorical parameters, such as changes in fluid leakage as demonstrated by 
fluorescein angiography, frequency and percentage of participants will be summarized.  
4.4 
Handling of Missing Values 
If IP compliance cannot be determined for a participant due to missing capsule counts, IP 
compliance will be imputed by taking the median of all available capsule counts recorded at 
previous study visits. 
All other missing observations will be excluded from analyses. 
4.5 
Handling Duplicate Assessments 
If participants completed assessments at both scheduled and supplementary visits, the assessments 
from the scheduled visit will be considered in the analysis and tabular summaries. However, if an 
assessment is completed only at supplementary visits, then the assessments from the most recent 
supplementary visit will be included in the analysis and tabular summaries. Results of all 
assessments, including those performed during supplementary visits, will be included in the 
listings. 
4.6 
Software for Analyses 
Statistical analyses will be performed using SAS version 9.4 or higher or R v3.6.1 or higher.  
All tables, listings and figures presented in the analysis will be created using either SAS v9.4 or 
Rv3.6.1 or higher. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 17 
5.0 
PARTICIPANT DISPOSITION 
Overall participant disposition including the number and percentage of participants enrolled, 
completed 12 months of treatment, completed the study and discontinued the study early will be 
summarized. Reasons for study discontinuation will also be summarized (Table 1). The number 
and percentage of participants who withdraw from IP due to safety, including due to vision loss 
(manually identified based on investigator’s comments for those participants with reason for 
withdrawal from IP indicated as “safety withdrawal”) and AEs (reason for withdrawal from IP 
indicated as “safety withdrawal” for the occurrence of AEs assessed as being related to study IP 
that preclude further administration of IP) will be included. Further, the number and percentage of 
participants deemed to have worsening disease will be included. Worsening disease is defined as 
loss of 15 or more ETDRS letters of vision compared to baseline OR a ≥ 1-step increase in the 
logOCT scale. This table will be based on the enrolled population. Data will be presented by 
treatment arm.  
Participant flow as outlined in Figure 1 will also be presented.  
If a participant terminates from the study at Month 12 but completes the ophthalmic assessments 
at the Month 12 visit, they will be counted as having completed follow-up through Month 12. 
Similarly, if a participant discontinues IP or is deemed to have worsening disease at the Month 12 
visit, the event will be considered to have occurred after Month 12. 
6.0 
PARTICIPANT CHARACTERISTICS 
These presentations will be based on the enrolled population. 
6.1 
Participant Demographics 
Demographic charteristics collected include baseline age, sex, race and ethnicity. Demographic 
data will be summarized by treatment as outlined in Table 2 and listed in Listing 1. This table will 
be based on the enrolled population. The listing will include the registration date of participants as 
well as the eye that was selected to be the study eye and the treatment to which participants were 
randomized.  


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 18 
6.2 
Medical and Ophthalmic History 
The total number and percentage of participants with a history of medical and ocular conditions, 
medications, and ocular procedures will be summarized. History of ocular conditions and 
procedures will also be summarized by eye (study eye and fellow eye) and treatment (Table 3). 
Medical and ocular history will also be listed; the listing will include the date of diagnosis and/or 
time since diagnosis at baseline for select conditions and procedures.  
Any findings from the physical examination at baseline will be included in a listing. 
7.0 
PARTICIPANT COMPLIANCE 
These presentations will be based on the enrolled population.  
7.1 
Protocol Deviations and Unanticipated Problems 
The total number of protocol deviations and unanticipated problems and the number and 
percentage of participants with deviations and unanticipated problems will be summarized.  
The number of events per participant and type (serious or not serious) and outcome of events will 
also be summarized (Table 4). Listings of participant specific and non-participant specific protocol 
deviations and unanticipated problems will be presented.  
7.1.1 IP Compliance Deviations 
This listing will present the number of doses taken, the number of doses missed, the expected 
number of doses taken, and the compliance rates for each participant (Listing 2). For each 
participant, the number of expected overall doses will be calculated as follows: 
𝑁 𝐷𝑜𝑠𝑒𝑠 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑= (𝐷𝑎𝑡𝑒 𝐿𝑎𝑠𝑡 𝑠𝑡𝑢𝑑𝑦 𝑣𝑖𝑠𝑖𝑡 𝑎𝑡𝑡𝑒𝑛𝑑𝑒𝑑−𝐷𝑎𝑡𝑒 𝐹𝑖𝑟𝑠𝑡 𝑑𝑎𝑡𝑒 𝐼𝑃 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑒𝑑) ∗2 
If participants took IP on the date they withdrew from the study or completed the study, the number 
of expected doses overall will be calculated as follows: 
𝑁 𝐷𝑜𝑠𝑒𝑠 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑= (𝐷𝑎𝑡𝑒 𝐿𝑎𝑠𝑡 𝑠𝑡𝑢𝑑𝑦 𝑣𝑖𝑠𝑖𝑡 𝑎𝑡𝑡𝑒𝑛𝑑𝑒𝑑−𝐷𝑎𝑡𝑒 𝐹𝑖𝑟𝑠𝑡 𝑑𝑎𝑡𝑒 𝐼𝑃 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑒𝑑+ 1) ∗2 
The site will report the number of pills taken based on self-reported information as recorded in the 
pill diary. The number of doses taken and missed will be calculated for each participant as: 
𝑁 𝐷𝑜𝑠𝑒𝑠 𝑡𝑎𝑘𝑒𝑛= 𝑁 𝑃𝑖𝑙𝑙𝑠 𝑑𝑖𝑠𝑝𝑒𝑛𝑠𝑒𝑑−𝑁 𝑃𝑖𝑙𝑙𝑠 𝑟𝑒𝑡𝑢𝑟𝑛𝑒𝑑 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 19 
𝑁 𝐷𝑜𝑠𝑒𝑠 𝑚𝑖𝑠𝑠𝑒𝑑= 𝑁 𝐷𝑜𝑠𝑒𝑠 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑−𝑁 𝐷𝑜𝑠𝑒𝑠 𝑡𝑎𝑘𝑒𝑛 
Negative values will indicate participants who took excess IP.  
Compliance rates will be calculated as: 
𝐶𝑜𝑚𝑝𝑙𝑖𝑎𝑛𝑐𝑒 𝑟𝑎𝑡𝑒= (𝑁 𝐷𝑜𝑠𝑒𝑠 𝑡𝑎𝑘𝑒𝑛/𝑁 𝐷𝑜𝑠𝑒𝑠 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑) ∗100 
When IP compliance cannot be determined for a participant during any visit due to missing capsule 
counts, IP compliance will be imputed by taking the median of all available capsule counts 
recorded at previous study visits.  
Participants with compliance rates less than 80% will be flagged. 
7.2 
Study Procedure Deviations 
This table will present the number of procedures not completed, the expected number of 
procedures completed, and the percentage of procedures missed by participant, procedure and 
collectively for all participants, cumulatively throughout the study (Table 5). Number of 
procedures not completed is defined when the site reports a missed procedure or when the protcol 
monitors note a missed procedure at a site, and will be presented as a sum. Expected number of 
procedures completed is defined based on the study flowsheet included in the protocol, and will 
also be presented as a sum. Percentage of procedures missed will be calculated as follows: 
(𝑁 𝑝𝑟𝑜𝑐𝑒𝑑𝑢𝑟𝑒𝑠 𝑛𝑜𝑡 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑/𝑁 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑝𝑟𝑜𝑐𝑒𝑑𝑢𝑟𝑒𝑠 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑑) ∗100   
7.3 
Visit Schedule Deviations 
This table will present the number of expected visits, number of missed study visits, the percentage 
of missed study visits, the number of out of window visits, and the percentage of out of window 
visits for each individual participant and collectively for all participants, cumulatively throughout 
the study (Table 6). Number of expected, missed and out of window study visits will be calculated 
from the study flowsheet and will all be presented as sums. The percentage of missed study visits 
will be calculated as: 
(𝑁 𝑣𝑖𝑠𝑖𝑡𝑠 𝑚𝑖𝑠𝑠𝑒𝑑/𝑁 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑖𝑠𝑖𝑡𝑠) ∗100   
Similarily, the percentage of out of window study visits will be calculated as: 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 20 
(𝑁 𝑣𝑖𝑠𝑖𝑡𝑠 𝑜𝑢𝑡 𝑜𝑓 𝑤𝑖𝑛𝑑𝑜𝑤/𝑁 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑣𝑖𝑠𝑖𝑡𝑠) ∗100   
8.0 
TREATMENT 
Information related to injections administered at each visit will be listed. 
9.0 
STOPPING THE STUDY  
If a participant meets one of the criteria for stopping the study listed in Section 3.2.3, a listing 
containing site, participant ID, date of last contact, visit number, reason for termination and 
comments related to termination will be constructed.                                         
10.0 
PRIMARY OUTCOMES ANALYSIS 
The primary outcome is the difference in mean change of BCVA, as measured in ETDRS letters, 
between the placebo and minocycline groups in the study eye at 12 months compared to baseline. 
BCVA at baseline as well as change from baseline at Month 12 will be summarized for both 
treatment arms (Table 7). Interval estimates of mean change in BCVA will also be constructed. 
The difference in mean change between the two groups at Month 12 will be calculated as the mean 
change from baseline at Month 12 for treatment arm 1 minus the mean change from baseline at 
Month 12 for treatment arm 2. Manifest refraction values for BCVA will be used when available. 
This analysis will be based on the primary analysis population.  
Additional presentations stratified by site will be constructed as appropriate. 
Exploratory nonparametric statistical analyses will be conducted as appropriate.  
Participants who were exposed to recent (< three months) systemic steroid or systemic anti-VEGF 
prior to enrolling will be analyzed separately as appropriate to assess for any possible confounding 
effects for treatment benefit.  
11.0 
SECONDARY OUTCOMES ANALYSIS 
These analyses will be based on the safety population who completed the respective visits.  
Additional presentations stratified by site will be constructed as appropriate. 
Exploratory nonparametric statistical analyses will be conducted as appropriate. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 21 
Participants who were exposed to recent (< three months) systemic steroid or systemic anti-VEGF 
prior to enrolling will be analyzed separately as appropriate to assess for any possible confounding 
effects for treatment benefit. 
11.1 
Number of Bevacizumab Injections 
The number of bevacizumab injections from baseline to 12 months and from baseline to 24 months 
will be tabulated by participant (Table 8). Additionally, the average number of injections between 
baseline and Months 12 and 24 will be calculated for each treatment arm, and the difference in the 
number of injections between the two groups will be presented (Table 9). The difference in the 
number of injections between the two groups will be calculated as the number of injections in 
treatment arm 1 minus the number of injections in treatment arm 2.  
11.2 
Macular Sensitivity 
Mean change in macular sensitivity in the study eye, as measured by microperimetry, from 
baseline at Months 3, 6, 12, 18 and 24 will be summarized by treatment arm (Table 10). The 
difference in mean macular sensitivity between the two groups will also be presented. The mean 
difference in macular sensitivity between the two groups at a visit will be calculated as the mean 
change from baseline in treatment arm 1 minus the mean change from baseline in treatment arm 2.  
11.3 
Best-Corrected Visual Acuity (BCVA) 
The mean change in ETDRS BCVA of the study eye at 24 months compared to baseline will be 
analyzed similar to the primary outcome detailed in section 10.0 (Table 11). Manifest refraction 
values for BCVA will be used when available.  
11.4 
Optical Coherence Tomography (OCT) 
The changes in retinal thickness in the study eye, as measured by OCT, at 6, 12, 18 and 24 months 
compared to baseline will be summarized by treatment arm, and interval estimates of the mean 
change will be constructed (Table 12). The difference in retinal thickness between the two groups 
will also be presented. The difference in retinal thickness between the two groups at a visit will be 
calculated as the mean change from baseline in treatment arm 1 minus the mean change from 
baseline in treatment arm 2. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 22 
11.5 
Improvement of ≥ 1 logOCT Scale Step 
The number of participants improving ≥ 1 logOCT scale step at 12 and 24 months compared to 
baseline in the study eye will be presented by treatment arm (Table 13). The difference in the 
number of participants improving ≥ 1 logOCT scale step from baseline will be calculated as the 
number of participants improving in treatment arm 1 minus the number of participants improving 
in treatment arm 2. Improvement of ≥ 1 logOCT scale step is defined as a decrease of ≥ 1-step on 
the logOCT scale, where 
𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑙𝑜𝑔𝑂𝐶𝑇= log (𝑓𝑜𝑙𝑙𝑜𝑤𝑢𝑝 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠/300) −log (𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠/300). 
A decrease in one-step is considered clinically significant (7). A one-step decrease is equivalent to 
at least a 20% improvement of central macular thickness and represents greater than twice the 
variability of retinal thickness measurements (approximately 25-30 microns). The table below 
presents examples of OCT measurements with their corresponding LogScore, where 
𝐿𝑜𝑔𝑆𝑐𝑜𝑟𝑒= 10 ∗log(𝑂𝐶𝑇). 
OCT and Corresponding LogScores (7) 
LogScore 
OCT (µm) 
0 
300 
0.5 
337 
1 
378 
1.5 
424 
2 
475 
2.5 
533 
3 
599 
3.5 
672 
4 
754 
4.5 
846 
5 
949 
5.5 
1064 
6 
1194 
6.5 
1340 
11.6 
Changes in Fluid Leakage 
Changes in the fluid leakage in the macula of the study eye, as demonstrated by fluorescein 
angiography, at 12 and 24 months compared to baseline will be summarized by treatment arm 
(Table 14). The difference in changes in fluid leakage between the two groups will also be 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 23 
presented as the change in fluid leakage in treatment arm 1 minus the change in fluid leakage in 
treatment arm 2.  
12.0 
SAFETY ANALYSIS 
These analyses will be based on the safety population, unless otherwise specified. All relevant 
information will be listed; data for all enrolled participants will be included in the listings.  
Relevant data may be plotted against time.  
Additional presentations stratified by site will be constructed as appropriate. 
12.1 
Adverse Events (AEs) 
All AEs reported will be summarized by treatment arm and overall. Total number and percentage 
of particpants with AEs will be presented by severity, ocular specification, outcome, and relation 
to IP (Table 15). AEs will also be summarized by system organ class (SOC) and preferred term 
(PT) (Table 16). If sufficient data is present, summaries similar to Table 15 and Table 16 will be 
generated for all serious adverse events (SAEs), and summaries similar to Table 16 will be 
presented for natural progression of the disease events.  
All AEs and events corresponding to natural progressions of the disease will be listed.  
12.2 
Withdrawal from IP Due to Vision Loss and Adverse Events and Participants with 
Worsening Disease 
Participants who discontinue IP due to vision loss and adverse events will be summarized in  
Table 1. Participants who are deemed to have worsening disease at any point during follow-up will 
also be presented in Table 1. Worsening disease is defined as a loss of 15 or more ETDRS letters 
of vision compared to baseline OR as 1-step increase in the logOCT scale.   
12.3 
Best-Corrected Visual Acuity 
Visual acuity will be collected at baseline and all follow-up visits for both eyes. Total letters read 
at each visit and change from baseline at each follow-up visit will be presented overall and by 
treatment arm for both the study and fellow eyes in Table 17. The number and percentage of 
participants with ≥ 10 letter change at each visit will also be included. Manifest refraction values 
for BCVA will be used when available. 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 24 
Mean BCVA will be plotted over time for the minocycline and placebo treatment arms for both 
the study and fellow eyes (Figure 2). Individual BCVA will also be plotted over time for both eyes 
(Figure 3).  
12.4 
Optical Coherence Tomography (OCT) 
Central retinal thickness, as measured by OCT, is assessed at all visits for both eyes. Central retinal 
thickness and change from baseline at each follow-up visit will be presented overall and by 
treatment arm for the study and fellow eyes in Table 18.  
Mean central retinal thickness will be plotted over time for the minocycline and placebo treatment 
arms for both the study and fellow eyes (Figure 4). Individual central retinal thickness will also be 
plotted over time for both eyes (Figure 5).  
12.5 
Intraocular Pressure (IOP) 
Intraocular pressure (IOP) is assessed at all visits for both eyes. IOP measurements at each visit 
and change from baseline at each follow-up visit will be summarized using descriptive statistics 
and will be presented overall and by treatment arm for both the study and fellow eyes (Table 19).  
12.6 
Thyroid Palpation Assessment and Review of Systems 
A thyroid palpation assessment and a review of systems are completed at every visit. The number 
and percentage of participants with clinically significant thyoid palpation findings will be 
summarized overall and by treatment arm (Table 20). The number and percentage of participants 
who experienced dizziness, sun sensitivity, or diarrhea between visits will also be summarized in 
Table 20.  
12.7 
Laboratory Assessments 
An acute care panel, hepatic panel and thyroid function testing will be performed at baseline, 
Month 2 and every four months thereafter (Months 6, 10, 14, 18 and 22), as well as the final visit 
at Month 24. Frequency and percentage of participants reporting laboratory abnormalities at 
baseline will be summarized with shift from baseline to each follow-up visit (Table 21).  


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 25 
12.8 
Other Safety Outcomes 
Exploratory analyses and/or descriptive summary statistics of color fundus photography (CFP), 
fluorescein angiogram (FA), microperimetry and other assessments will be performed as 
appropriate. 
13.0 
QUALITY ASSURANCE PLANS 
To ensure accurate, reliable study results, two statisticians will separately analyze and compare the 
primary study outcome. All SAS or R code use to generate primary and secondary outcomes will 
undergo a code validation by an independent statistician or SAS programmer. Documentation 
related to code validation audits will be maintained on file at the Coordinating Center. 
14.0 
REFERENCES 
1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in 
Australia. The Blue Mountains Eye Study. Archives of ophthalmology 1996; 114(10): 1243- 
1247.  
2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the 
Beaver Dam Eye Study. Transactions of the American Ophthalmological Society 2000; 98: 
133-141; discussion 141-133. 
3. Zemke D, Majid A. The potential of minocycline for neuroprotection in human neurologic 
disease. Clin Neuropharmacol 2004; 27(6): 293-298.  
4. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracycline 
derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation 
of microglia. J Neurosci 2001; 21(8): 2580-2588.  
5. Bosco A, Inman DM, Steele MR et al. Reduced retina microglial activation and improved 
optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. 
Investigative ophthalmology & visual science 2008; 49(4): 1437-1446.  
6. Yang LP, Zhu XA, Tso MO. A possible mechanism of microglia-photoreceptor crosstalk. 
Molecular vision 2007; 13: 2048-2057.  


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 26 
7. Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research 
Network. A proposed method of logarithmic transformation of optical coherence tomography 
data for use in clinical research. Ophthalmology. 2010 Aug;117(8): 1512-6. 
 
 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 27 
15.0 
MOCK SHELLS 
TABLES 
Table 1: Participant Disposition 
 
Disposition 
Treatment Arm 1 
(N=X)1 
Treatment Arm 2 
(N=X)1 
Total 
(N=X)1 
Enrolled 
x (x%) 
x (x%) 
x (x%) 
Completed Follow-up Through Month 12 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
Completed Study 
     Completed Follow-up 
     Terminated per protocol 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
Discontinued IP Early 
     Prior to Month 12 
     After Month 12 
     Reason 
          Participant non-compliance 
          Safety Withdrawal 
               Vision loss2 
               AEs3 
          Other 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
Discontinued Study Early 
     Prior to Month 12 
     After Month 12 
     Reason 
          AE/intercurrent illness 
          Death 
          Requested termination 
          Other 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
Deemed to Have Worsening Disease4 
     Prior to Month 12 
     After Month 12 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
1 Column header counts and denominators are the number of participants in the enrolled population in each treatment arm and 
overall. Percentages are rounded to the nearest whole number. 
2 Manually identified based on investigator’s comments for those participants with reason for withdrawal from IP as “safety 
withdrawal”. 
3 Participants with reason for withdrawal from IP indicated as “safety withdrawal” for the occurrence of AEs assessed as being 
related to the study IP that preclude further administration of IP.  
4 Worsening disease is defined as a loss of 15 or more ETDRS letters of vision compared to baseline OR a 1-step increase in 
the logOCT scale.  
 
 
 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 28 
Table 2: Demographic Information by Treatment Arm 
 
Demographic Characteristics 
Treatment Arm 1 
(N=X)1 
Treatment Arm 2 
(N=X)1 
Total 
(N=X)1 
Gender N (%) 
     Female 
     Male 
 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
Age Category (years) at Baseline N (%) 
     56-60 
     61-65 
     66-70 
     71-75 
     76-80 
     81-85 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Age (years) at Baseline 
     N 
     Mean (SD) 
     Median 
     Range (Min, Max) 
 
x 
x.x (x.x) 
x 
(x, x) 
 
x 
x.x (x.x) 
x 
(x, x) 
 
x 
x.x (x.x) 
x 
(x, x) 
Ethnicity N (%) 
     Hispanic or Latino 
     Not Hispanic or Latino 
 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
Race N (%) 
     Black 
     White 
     Unknown 
 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
1 Column header counts and denominators are the number of participants in the enrolled population in each treatment arm and 
overall. Percentages are rounded to the nearest whole number. 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 29 
Table 3: Medical and Ocular History 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
Conditions/Procedures 
Study Eye 
(N=X)1 
Fellow Eye 
(N=X)1 
Total 
(N=X)1,2 
Study Eye 
(N=X)1 
Fellow Eye 
(N=X)1 
Total 
(N=X)1,2 
Study Eye 
(N=X)1 
Fellow Eye 
(N=X)1 
Total 
(N=X)1,2 
Any Medical Condition 
     Renal disease 
     Hepatitis 
     Liver Failure 
     … 
 
 
 
 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Any Medication History 
     Systemic anti-VEGF 
     Systemic steroid 
 
 
 
 
x (x%) 
x (x%) 
x (x%) 
 
 
 
x (x%) 
x (x%) 
x (x%) 
 
 
 
 
x (x%) 
x (x%) 
x (x%) 
Any Ocular Condition 
     Recurrent RVO 
     RVO present > 18 months 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Any Ocular Procedure 
     Intravitreal steroid injection 
     Cataract surgery 
     Vitrectomy 
     … 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
1 Column header counts and denominators are the number of participants in the enrolled population in each treatment arm and overall. Percentages are rounded to the nearest whole number. 
2 If a participant reported an ocular condition or procedure in both eyes, the participant will only be counted once. 
 
 
  
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 30 
Table 4: Protocol Deviations and Unanticipated Problems 
 
 
Participant-Specific 
Non-Participant Specific 
Total 
 
Number of 
Events 
Number of Participants 
with Events 
(N=X)1 
Number of  
Events 
Number of 
Events 
All Events 
     Protocol Deviations 
     Unanticipated Problems 
 
x 
x 
x 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
x 
x 
x 
Number of Events per Participant 
     N 
     Mean (SD) 
     Median 
     Range (Min, Max) 
 
 
x 
x.x (x.x) 
x 
x, x 
 
 
 
Type 
     Serious 
     Not serious 
 
 
x 
x 
 
x (x%) 
x (x%) 
 
x 
x 
 
x 
x 
Outcome 
     Participant follow-up continues 
     Participant follow-up terminated 
     … 
 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
 
x 
x 
x 
1 Column header count and denominators are the number of participants in the enrolled population. Percentages are rounded to the nearest whole 
number. 
 
 
Table 5: Missed Study Procedures 
 
Category 
Participant ID/ 
Procedure 
Number of 
Expected 
Procedures 
Number of Missed 
Procedures 
Percentages of 
Missed Procedures 
Participant 
001 
xx 
xx 
x.x 
 
002 
xx 
xx 
x.x 
 
003 
xx 
xx 
x.x 
 
… 
xx 
xx 
x.x 
 
… 
xx 
xx 
x.x 
 
 
 
 
 
Procedure 
Acute Care Panel 
xx 
xx 
x.x 
 
Adverse Event 
Assessment 
xx 
xx 
x.x 
 
BCVA (ETDRS) 
xx 
xx 
x.x 
 
… 
xx 
xx 
x.x 
 
… 
xx 
xx 
x.x 
 
 
 
 
 
Total 
 
xx 
xx 
x.x 
 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 31 
Table 6: Missed and Out of Window Study Visits 
 
Participant 
ID 
Number of 
Expected Visits 
Number of 
Missed Visits 
Percentage of 
Missed Visits 
Number of Out 
of Window Visits 
Percentage of Out 
of Window Visits 
Visits Missed or Out 
of Window 
001 
xx 
xx 
x.x 
xx 
x.x 
xxx 
002 
xx 
xx 
x.x 
xx 
x.x 
 
… 
xx 
xx 
x.x 
xx 
x.x 
 
Total 
xx 
xx 
x.x 
xx 
x.x 
 
 
 
 
Table 7: Analysis of Primary Outcome of Change in BCVA of the Study Eye from Baseline at Month 12 
 
 
Treatment Arm 1 
Treatment Arm 2 
Difference1 
Visit 
BCVA 
(letters read) 
Δ 
(letters read) 
BCVA 
(letters read) 
Δ 
(letters read) 
BCVA 
(letters read) 
Δ 
(letters read) 
Baseline 
     N 
     Mean (SD) 
     95% Confidence Interval 
 
x 
x (x) 
(x, x) 
 
 
x 
x (x) 
(x, x) 
 
 
 
x (x) 
(x, x) 
 
 
 
 
 
 
 
 
Month 12 
     N 
     Mean (SD) 
     95% Confidence Interval 
 
x 
x (x) 
(x, x) 
 
x 
x (x) 
(x, x) 
 
x 
x (x) 
(x, x) 
 
x 
x (x) 
(x, x) 
 
 
x (x) 
(x, x) 
 
 
x (x) 
(x.x, x.x) 
Δ indicates change from baseline. 
1 Difference is defined as Treatment Arm 1 – Treatment Arm 2. Negative values indicate that participants in Treatment Arm 2 experienced a higher visual acuity or a more 
positive change from baseline at Month 12.   
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 32 
Table 8: Analysis of Secondary Outcome of Number of Bevacizumab Injections by Participant from Baseline to Month 12 and 
from Baseline to Month 24 
 
Participant ID 
Treatment Arm 
Visit Period 
Number of Bevacizumab Injections 
001 
T1/T2 
Baseline to Month 12 
xx 
 
 
Baseline to Month 24 
xx 
 
 
 
 
002 
T1/T2 
Baseline to Month 12 
xx 
 
 
Baseline to Month 24 
xx 
… 
… 
… 
… 
 
 
 
Table 9: Analysis of Secondary Outcome of Summary of Bevacizumab Injections by Treatment Arm from Baseline to Month 
12 and from Baseline to Month 24 
 
Visit Period 
Treatment Arm 1 
(N=X)1 
Treatment Arm 2 
(N=X)1 
Difference2 
Baseline to Month 12 
     Number of Injections 
     Mean 
 
 
xx 
x.x 
 
xx 
x.x 
 
xx 
x.x 
 
 
 
 
Baseline to Month 24 
     Number of Injections 
     Mean 
 
xx 
x.x 
 
xx 
x.x 
 
xx 
x.x 
1 Column header counts are the number of participants in the safety population in each treatment arm and overall. 
2 Difference is defined as Treatment Arm 1 – Treatment Arm 2. Negative values indicate that participants in Treatment Arm 2 received more injections during the respective 
visit period. 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 33 
Table 10: Analysis of Secondary Outcome of Change in Macular Sensitivity as Measured 
by Microperimetry from Baseline at Months 3, 6, 12, 18 and 24 
This table will be similar to Table 7. The rows corresponding to the 95% confidence interval will 
be excluded.  
 
Table 11: Analysis of Secondary Outcome of Change in BCVA of the Study Eye from 
Baseline at Month 24 
This table will be similar to Table 7. 
 
Table 12: Analysis of Secondary Outcome of Change in Central Retinal Thickness of the 
Study Eye from Baseline at Months 6, 12, 18 and 24 
This table will be similar to Table 7.  
 
Table 13: Analysis of Secondary Outcome of Number of Participants Improving ≥ 1 
logOCT Scale Step in the Study Eye at 12 and 24 Months Compared to Baseline 
 
Visit 
Treatment Arm 1 
N (%)1 
Treatment Arm 2 
N (%)1 
Difference2 
Month 12 
x (x%) 
x (x%) 
x 
Month 24 
x (x%) 
x (x%) 
x 
1 Denominators are the number of participants in the safety population in each treatment arm and overall. Percentages are 
rounded to the nearest whole number. 
2 Difference is defined as Treatment Arm 1 – Treatment Arm 2. Negative values indicate that more participants in Treatment 
Arm 2 improved by ≥ 1 logOCT scale step at the respective visit compared to baseline. 
 
Table 14: Analysis of Secondary Outcome of Change in Fluid Leakage in the Macula in the 
Study Eye at 12 and 24 Months Compared to Baseline 
 
Visit 
Treatment Arm 1 
N (%)1 
Treatment Arm 2 
N (%)1 
Difference2 
Month 12 
     Increase 
     Decrease 
     No Change 
 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
 
 
 
 
Month 24 
     Increase 
     Decrease 
     No Change 
 
x (x%) 
x (x%) 
x (x%) 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
1 Denominators are the number of participants in the safety population in each treatment arm and overall. Percentages are 
rounded to the nearest whole number. 
2 Difference is defined as Treatment Arm 1 – Treatment Arm 2. Negative values indicate that more participants in Treatment 
Arm 2 experienced a certain change in fluid leakage at the respective visit compared to baseline.  
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 34 
Table 15: Summary of Adverse Events 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
All AEs 
x (x%) 
x 
x (x%) 
x 
x (x%) 
x 
Serious Adverse Events 
x (x%) 
x 
x (x%) 
x 
x (x%) 
x 
Severity 
     Mild 
     Moderate 
     Severe 
     Life-threatening 
     Death 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
x 
Eye 
     Non-ocular 
     Study eye 
     Fellow eye 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
Outcome 
     Resolved 
     Resolved with sequalae 
     Death 
     Resolved by convention 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
 
x 
x 
x 
x 
Relation to IP 
     Yes 
     No 
 
x (x%) 
x (x%) 
 
x 
x 
 
x (x%) 
x (x%) 
 
x 
x 
 
x (x%) 
x (x%) 
 
x 
x 
1 Denominators are the number of participants in the safety population in each treatment arm and overall. Percentages are rounded to the nearest whole number. 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 35 
Table 16: Summary of Adverse Events by System Organ Class (SOC) and Preferred Term (PT) 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
System Organ Class/ 
Preferred Term 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
Participants 
with Events 
N (%)1 
Number of 
Events 
N 
SOC1 
     PT1 
     PT2 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
SOC2 
     PT1 
     PT2 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
x (x%) 
x (x%) 
x (x%) 
x 
x 
x 
… 
 
 
 
 
 
 
… 
 
 
 
 
 
 
1 Denominators are the number of participants in the safety population in each treatment arm and overall. Percentages are rounded to the nearest whole number. 
 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 36 
Table 17: Summary of Visual Acuity Over Time 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
 
BCVA 
(letters read) 
Δ 
(letters read) 
BCVA 
(letters read) 
Δ 
(letters read) 
BCVA 
(letters read) 
Δ 
(letters read) 
Visit 
Study 
Eye 
Fellow 
Eye 
Study 
Eye 
Fellow 
Eye 
Study 
Eye 
Fellow 
Eye 
Study 
Eye 
Fellow 
Eye 
Study 
Eye 
Fellow 
Eye 
Study 
Eye 
Fellow 
Eye 
Baseline 
     N 
     Median 
     Mean (SD) 
     (Min, Max) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
 
 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
 
 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
 
 
Month 1 
     N 
     Median 
     Mean (SD) 
     (Min, Max) 
     Change of ≥ 10 letters, N(%)1     
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
 
x 
x.x 
x (x) 
(x, x) 
 
x 
x.x 
x (x) 
(x, x) 
x (x%) 
Month 2 
 
 
 
 
 
 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
Month 24 
 
 
 
 
 
 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
Δ indicates change from baseline. 
1 Denominators are the number of participants in the safety population in each treatment arm and overall with data at the given visit. Percentages are rounded to the nearest whole number. 
 
 
 
 
 
 
 
 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 37 
Table 18: Summary of Central Retinal Thickness Over Time 
This table will be similar to Table 17. The row corresponding to Change of ≥ 10 letters will be excluded. 
 
Table 19: Summary of IOP Over Time 
This table will be similar to Table 17. The row corresponding to Change of ≥ 10 letters will be excluded. 
 
 
Table 20: Results of Thyroid Palpation Assessment and Review of Systems Over Time 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
 
Significant 
Findings 
Review of Systems 
Significant 
Findings 
Review of Systems 
Significant 
Findings 
Review of Systems 
Visit 
Thyroid 
Palpation 
Dizziness 
Sun 
Sensitivity Diarrhea 
Thyroid 
Palpation 
Dizziness 
Sun 
Sensitivity Diarrhea 
Thyroid 
Palpation 
Dizziness 
Sun 
Sensitivity Diarrhea 
Baseline 
x (x%) 
 
 
 
x (x%) 
 
 
 
x (x%) 
 
 
 
Month 1 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Month 2 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
… 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
… 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Month 24 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
x (x%) 
Denominators are the number of participants in the safety population in each treatment arm and overall with data at the given visit. Percentages are rounded to the nearest whole number. 
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 38 
Table 21: Summary of Laboratory Assessments Over Time 
 
 
Treatment Arm 1 
Treatment Arm 2 
Total 
Visit 
Participants 
with Lab 
Assessments  
N1 
Abnormal 
Lab 
Assessments 
N (%)2 
Any Δ 
N (%)2 
Clinically 
Significant 
Δ 
N (%)2 
Participants 
with Lab 
Assessments  
N1 
Abnormal 
Lab 
Assessments 
N (%)2 
Any Δ 
N (%)2 
Clinically 
Significant 
Δ 
N (%)2 
Participants 
with Lab 
Assessments  
N1 
Abnormal 
Lab 
Assessments 
N (%)2 
Any Δ 
N (%)2 
Clinically 
Significant 
Δ 
N (%)2 
Baseline 
x 
x (%) 
 
 
x 
x (%) 
 
 
x 
x (%) 
 
 
Month 2 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
Month 6 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
Month 10 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
… 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
… 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
Month 22 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
Month 24 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
x 
 
x (%) 
x (%) 
Δ indicates changes from baseline 
1 Participants in the safety population in each treatment arm and overall with laboratory assessment data at the given visit. 
2 Denominators are the number of participants in the safety population in each treatment arm and overall with laboratory assessment data at the given visit.  
 
 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 39 
FIGURES 
Figure 1: Consort Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomized 
N = X 
Allocated to T1 
N = X 
Allocated to T2 
N = X 
Prior to Month 12 
Discontinued intervention: N = X 
 
Lost to follow-up: N = X 
Prior to Month 12 
Discontinued intervention: N = X 
 
Lost to follow-up: N = X 
Analyzed (Primary – Month 12) 
N = X 
Between Month 12 and Month 24 
Discontinued intervention: N = X 
 
Lost to follow-up: N = X 
Analyzed (Secondary – Month 24) 
N = X 
Analyzed (Primary – Month 12) 
N = X 
Between Month 12 and Month 24 
Discontinued intervention: N = X 
 
Lost to follow-up: N = X 
Analyzed (Secondary – Month 24) 
N = X 


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 40 
Figure 2: Mean Best-Corrected Visual Acuity Over Time by Treatment Arm 
 
 
 
 
 
 
 
 
 
Study Eye
Fellow Eye
eye
Mean BCVA (letters read)
Treatment Arm 2
Treatment Arm 1
0
5
10
15
20
25
Time from Baseline (Months)
60
65
70
75
80
60
65
70
75
80


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 41 
Figure 3: Best-Corrected Visual Acuity Over Time by Participant 
 
 
 
 
Figure 4: Mean Central Retinal Thickness Over Time by Treatment Arm 
This figure will be similar to Figure 2. 
Figure 5: Central Retinal Thickness Over Time by Participant 
This figure will be similar to Figure 3.  
 
10
9
8
7
6
5
4
3
2
1
id
BCVA (letters read)
Study Eye
Fellow Eye
0
5
10
15
20
25
Time from Baseline (Months)
50
60
70
80
70
75
80
85
90


MiCRVO SAP 
April 14, 2020 
Version 1.0 
Confidential 
Page 42 
LISTINGS 
Listing 1: Demographic Information by Participant 
 
Participant 
ID 
Treatment  
Arm 
Registration 
Date 
Study 
Eye 
Age 
Gender 
Race 
Ethnicity 
001 
xx 
mm/dd/yy 
xx 
xx 
xxx 
xxx 
xxx 
002 
xx 
mm/dd/yy 
xx 
xx 
xxx 
xxx 
xxx 
… 
xx 
mm/dd/yy 
xx 
xx 
xxx 
xxx 
xxx 
 
 
 
Listing 2: IP Compliance 
 
Participant 
ID 
Treatment 
Arm 
Number of 
Doses Taken 
Number of 
Doses Missed 
Expected Number 
of Doses Taken 
Compliance 
Rate (%) 
001 
xx 
xx 
xx 
xx 
x.x 
002 
xx 
xx 
xx 
xx 
x.x 
… 
xx 
xx 
xx 
xx 
x.x